Molecular modeling of bacterial polysaccharide antigens to inform future vaccine development by Hlozek, Jason
1 
Molecular modeling of bacterial polysaccharide 
antigens to inform future vaccine development 
Author: Jason Hlozek 
Supervisors: Neil Ravenscroft, Michelle Kuttel 
Thesis Presented for the Degree of 
DOCTOR OF PHILOSOPHY 
in the Department of Chemistry 




















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 













Molecular modeling of bacterial polysaccharide antigens to inform 
future vaccine development 
I, Jason Peter James Hlozek, declare the following: 
1. That the above-titled thesis is my own work, both in conception and execution,
apart from the normal guidance of my supervisor(s);
2. That in cases where others’ work has been cited, this has been acknowledged
and referenced;
3. That no part of this thesis has been submitted in the past, or is being, or is to be
submitted for another degree at this or at any other University;
4. That I grant the University of Cape Town free license to reproduce this thesis in
whole or in part, for the purpose of research.
I hereby present this report in fulfilment of the requirements for the degree of Doctor 
of Philosophy in the Department of Chemistry at the University of Cape Town. 
___________________ 
Doctoral Candidate’s Signature 
October 2020 
3 
I confirm that I have been granted permission by the University of Cape 
Town’s Doctoral Degrees Board to include the following publication(s) in 
my PhD thesis, and where co-authorships are involved, my co-authors 
have agreed that I may include the publication(s): 
a. Hlozek, J.; Kuttel, M. M.; Ravenscroft, N., Conformations of Neisseria meningitidis
serogroup A and X polysaccharides: The effects of chain length and O-acetylation. 
Carbohydr. Res. 2018, 465, 44-51. 
b. Hlozek, J.; Ravenscroft, N.; Kuttel, M. M., Modeling the conformations of Neisseria
meningitidis serogroup a CPS and a carba-analogue: Implications for vaccine 
development. Carbohydr. Res. 2019, 486, 107838. 
c. Hlozek, J.; Ravenscroft, N.; Kuttel, M. M., Effects of Glucosylation and O-Acetylation
on the Conformation of Shigella flexneri Serogroup 2 O-Antigen Vaccine Targets. J. 
Phys. Chem. B 2020, 124 (14), 2806-2814. 
d. Hlozek, J.; Owen, S.; Ravenscroft, N.; Kuttel, M. M., Molecular Modeling of the
Shigella flexneri Serogroup 3 and 5 O-Antigens and Conformational Relationships for a 
Vaccine Containing Serotypes 2a and 3a. (Submitted, Under review).
Signature: Date: 16 September 2020 
Student Name: Jason Hlozek Student Number: HLZJAS001 
4 
 
Table of Contents 
Abstract ................................................................................................................................... 8 
Abbreviations ........................................................................................................................... 9 
Acknowledgments ................................................................................................................. 10 
List of publications ................................................................................................................. 11 
Conference presentations ..................................................................................................... 14 
Introduction ........................................................................................................................... 15 
1.1 The effectiveness of vaccines in controlling disease .................................................... 15 
1.2 Molecular dynamics theory .......................................................................................... 19 
1.3 Computational methodology ....................................................................................... 23 
1.4 Aims ............................................................................................................................. 24 
1.5 Dissertation structure................................................................................................... 25 
Modeling the CPS of N. meningitidis serogroup A and X ....................................................... 27 
2.1 Foreword ...................................................................................................................... 27 
2.2 Abstract ........................................................................................................................ 30 
2.3 Introduction ................................................................................................................. 31 
2.4 Results and discussion .................................................................................................. 35 
2.4.1 MenA CPS backbone conformation ....................................................................... 35 
2.4.2 MenX conformation ............................................................................................... 39 
2.4.3 Conformation of O-acetylated MenA .................................................................... 42 
5 
 
2.5 Conclusions .................................................................................................................. 45 
2.6 Experimental ................................................................................................................ 46 
2.6.1 Molecular dynamics simulations ........................................................................... 46 
2.6.2 Post-simulation analysis ........................................................................................ 48 
2.6.3 NMR analysis ......................................................................................................... 49 
2.7 Supplementary information ......................................................................................... 51 
Analysis of a chemically-stable mimic of N. meningitidis serogroup A................................... 52 
3.1 Foreword ...................................................................................................................... 52 
3.2 Abstract ........................................................................................................................ 55 
3.3 Introduction ................................................................................................................. 56 
3.4 Results and discussion .................................................................................................. 59 
3.4.1 Oligosaccharide chain conformations .................................................................... 60 
3.4.2 Glycosidic linkage conformations .......................................................................... 64 
3.4.3 Chain length effects ............................................................................................... 69 
3.5 Conclusions .................................................................................................................. 71 
3.6 Experimental ................................................................................................................ 72 
3.6.1 Molecular dynamics ............................................................................................... 72 
3.6.2 Data analysis .......................................................................................................... 73 
Conformations of S. flexneri serogroup 2: optimizing the design of a serotype 2a 
vaccine ................................................................................................................................... 75 
6 
 
4.1 Foreword ...................................................................................................................... 75 
4.2 Abstract ........................................................................................................................ 78 
4.3 Introduction ................................................................................................................. 79 
4.4 Materials and methods ................................................................................................ 82 
4.4.1 Disaccharide PMF calculations ............................................................................... 83 
4.4.2 Molecular dynamics ............................................................................................... 83 
4.4.3 Data analysis .......................................................................................................... 84 
4.5 Results .......................................................................................................................... 85 
4.5.1 O-Ag chain extension and flexibility ....................................................................... 86 
4.5.2 O-Ag chain conformations ..................................................................................... 88 
4.5.3 O-Ag glycosidic linkage conformations .................................................................. 92 
4.6 Discussion and conclusions .......................................................................................... 96 
4.7 Associated content ....................................................................................................... 98 
4.8 Supplementary information ....................................................................................... 100 
Cross-protection from a S. flexneri multivalent vaccine including serotypes 2a and 3a ...... 103 
5.1 Foreword .................................................................................................................... 103 
5.2 Abstract ...................................................................................................................... 106 
5.3 Introduction ............................................................................................................... 107 
5.4 Materials and methods .............................................................................................. 111 
5.4.1 φ, ψ PMF calculations .......................................................................................... 112 
7 
 
5.4.2 Molecular dynamics ............................................................................................. 112 
5.4.3 Block averaging analysis ...................................................................................... 114 
5.4.4 Data analysis ........................................................................................................ 114 
5.5 Results ........................................................................................................................ 115 
5.5.1 Simulation convergence ...................................................................................... 116 
5.5.2 O-Ag flexibility ..................................................................................................... 116 
5.5.3 O-Ag chain conformations ................................................................................... 120 
5.5.4 O-Ag glycosidic linkage conformations ................................................................ 124 
5.6 Discussion ................................................................................................................... 130 
5.7 Conclusion .................................................................................................................. 131 
5.8 Supplementary information ....................................................................................... 134 
Discussion and conclusions .................................................................................................. 137 
References ........................................................................................................................... 150 
  




Polysaccharide conjugate vaccines have been pivotal in reducing the prevalence and 
severity of bacterial infectious diseases worldwide, preventing countless deaths. The 
effectiveness of a vaccine can be extended if the selected vaccine strains in a 
multivalent vaccine cross-protect against non-vaccine strains. Detailed knowledge of 
antigen structure and conformation is required for vaccine components to be 
rationally selected. However, experimental methods may not be able to ascertain the 
conformations of polysaccharide chains. To address this, molecular dynamics 
simulations can provide key theoretical insights on molecular conformation to 
rationalize cross-protection data and inform vaccine development.  
In this work, we use molecular dynamics to investigate the conformations of glycan 
antigens of Neisseria meningitidis and Shigella flexneri bacteria - causative agents of 
meningitis and diarrheal disease. For N. meningitidis, our modeling indicates why 
vaccination with serogroup A has not cross-protected against serogroup X infection, 
justifying the inclusion of serogroup X in future multivalent meningococcal vaccines. 
We also find that a chemically-stable carba-analogue of serogroup A has significant 
conformational differences to the native serogroup A chain, which does not support its 
use as a suitable serogroup A vaccine replacement. Our simulations of S. flexneri glycan 
antigens (serogroups Y, 2, 3, and 5) identify heuristics for the effects of substitution on 
backbone conformation and supports a proposed vaccine containing serotypes 2a 
(with O-acetylation) and 3a that will provide broad cross-protection. These findings can 
guide the rational selection of vaccine components to result in next-generation 




CPS  Capsular Polysaccharide 
LMICs  Low- and Middle-Income Countries 
LPS  Lipopolysaccharide 
MD  Molecular Dynamics 
MenA  Neisseria meningitidis serogroup A 
MenX  Neisseria meningitidis serogroup X 
NMR  Nuclear Magnetic Resonance 
O-Ag  O-antigen 
PMF  Potential of Mean Force 
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1.1 The effectiveness of vaccines in controlling disease 
Vaccination is a fundamental medical practice that reduces the morbidity and 
mortality rates of infectious diseases.5, 6 Vaccines prevent approximately 2.5 million 
deaths per year7 and typically reduce disease severity if subsequent infection occurs.8 
In previous decades, significant progress has been made in the number of diseases 
prevented by licensed vaccines as well as in the development of new vaccination 
technologies.9 However, vaccines do not always reach the most affected populations – 
approximately 20% of deaths in children under five years of age could be prevented by 
currently available vaccines.10-12  
These vaccine preventable diseases disproportionately affect low- and middle-income 
countries (LMICs) who often lack adequate health care infrastructure or the 
socioeconomic means to purchase vaccines.13 The greatest burden falls on the African 
continent where vaccination rates for common infectious diseases are typically below 
the global average14 and with a corresponding child mortality rate from vaccine 
preventable diseases accounting for as much as 50% of the global total.15 These 
diseases are becoming notably more serious with increasing development of antibiotic 
resistance, which renders many conventional treatments ineffective.16, 17 Therefore, 
the development of inexpensive and effective vaccines that prevent disease are key to 
reducing the extensive disease burden on Africa. In particular, the bacterial pathogens 
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that contribute to meningococcal and diarrheal diseases have long been major 
contributors to the severity of the African disease burden and are addressed 
specifically in this dissertation.  
Vaccines protect an individual that is susceptible to a particular disease by introducing 
a weakened form of that pathogen or a smaller constituent thereof to elicit a 
protective immune response.12 This trains the immune system to recognize the 
pathogen and it is subsequently primed to defend against natural infection if the 
pathogen is encountered in future. For infectious bacteria, vaccines commonly target 
the glycans expressed on the bacterial cell surface. These polysaccharides have 
tremendous structural variety given the large number of possible monosaccharide 
building blocks as well as the multiple hydroxyl groups through which the 
monosaccharides can be linked together.18 The unique polysaccharide chains are 
typically used as the defining antigen for classifying bacterial strains into serotypes and 
serogroups. These polysaccharide antigens can be obtained through purification from 
bacterial cultures, chemically synthesized, or made biosynthetically by recombinant 
expression.19 Modern vaccines further enhance the immunogenicity of polysaccharide 
components through conjugation to an antigenic protein carrier.20 
To date, significant progress has been made towards the development and licensure of 
bacterial polysaccharide-based vaccines.19, 21 Diseases are typically caused by several 
strains that circulate simultaneously in a given region, such as Neisseria meningitidis, 
Shigella flexneri, Streptococcus pneumoniae, Klebsiella pneumoniae, etc. Therefore, 
vaccines often need to consist of several serogroups/serotypes (vaccine valency) to 
provide broad protection. A key challenge in vaccine development is to design a 
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vaccine that provides maximal coverage against prevalent bacterial strains with 
minimal vaccine valency, reducing vaccine cost. The valency of a vaccine can be 
reduced if the selected vaccine serotype(s) can confer protection against closely 
related non-vaccine serotypes.  
Serotype cross-protection typically occurs between chemically similar strains within 
the same serogroup; however, similarity in primary structure alone is not a reliable 
predictor for cross-protection.22 For example, the first seven-valent vaccine against 
Streptococcus pneumoniae (PCV7) included serotype 19F and cross-protection was 
expected against the related serotype 19A. Both serotypes express a similar 
trisaccharide repeating unit (RU) with a difference in a single linkage position, yet 19A 
infection increased post-PCV7 vaccination23 and only limited cross-protection was 
observed from PCV7 in clinical study.24 Computational modeling could rationalize these 
findings with the discovery of conformational differences between the serotypes: 19F 
had a higher prevalence of extended conformations, while 19A instead adopted more 
compact structures with hairpin bends.25 Therefore, antibodies raised against the 19F 
chain are unlikely to recognize and bind to the conformations adopted by 19A with the 
same avidity, resulting in diminished cross-protection against 19A and explaining the 
increase in 19A infection after PCV7 vaccination.  
A second example is that of Neisseria meningitidis serogroups Y and W. Both 
serogroups have hexose-sialic acid RUs where the hexose residues are C-4 epimers 
(glucose for Y compared to galactose for W). Despite no structural change at a linkage 
position, clinical study reports unusual asymmetric cross-protection: vaccination with 
serogroup Y elicited a cross-protective antibody response against serogroup W in 71% 
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of volunteers, while vaccination with serogroup W only elicited cross-protective 
antibodies against serogroup Y in 30% of volunteers.26 Computational modeling of the 
polysaccharides chains revealed a dramatic difference in conformations: serogroup Y 
had a single dominant conformation while serogroup W instead adopted a range of 
conformational families, which included the dominant conformation of serogroup Y. 
These findings could rationalize the clinical data - the majority of antibodies raised 
against Y could also cross-react with a conformation adopted by W, however, only a 
small proportion of antibodies raised against the array of conformations expressed by 
W would recognize the single conformation of Y.27 Therefore, as even small structural 
changes can lead to significant differences in polysaccharide conformation and 
flexibility, a central assumption for cross-reactivity is that both chemical and 
conformational similarity are required for effective cross-protection to occur. 
A detailed understanding of antigen structure and conformation enables a rational 
approach towards the selection of suitable vaccine components in the vaccine design 
process. For glycans, the most common experimental methods for obtaining structural 
data are X-ray crystallography and Nuclear Magnetic Resonance (NMR) spectroscopy. 
However, although powerful, these methods are limited in the scope of information 
they provide. X-ray crystallography relies on the ability of the polysaccharide to 
crystallize (or co-crystallize with a bound antibody) and represents the glycan 
conformation in the solid phase, however, this may not be representative of the 
potential range of conformations adopted in solution. NMR is a powerful technique for 
determining molecular structure, yet, the resulting spectra represent the dynamic 
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average of polysaccharide conformations in solution and may be ambiguous for 
determining the conformation of flexible glycan chains.  
Computational modeling is increasingly employed to gain theoretical insight into 
glycan conformation, which may otherwise be inaccessible to experiment. As we 
transition from a history of empirically designed vaccines toward an age of rational 
vaccine design,28, 29 molecular modeling in combination with NMR data can be a 
powerful methodology to rationalize empirical cross-protection findings and guide 
future glycoconjugate vaccine design. 
1.2 Molecular dynamics theory 
Molecular simulations aim to reproduce the time dependent behavior of microscopic 
molecular systems in order to explain and predict physical phenomena. A molecular 
system can be fully described by solving the quantum mechanical wave functions of 
the system components; however, this is often computationally infeasible to compute 
even for small solvated systems. Instead, classical physics descriptions can be 
employed, which are much faster to compute and can sufficiently approximate the 
physical properties of much larger systems.30  
This work makes use of molecular dynamics (MD) simulations to provide detailed 
atomistic information of glycan antigen conformations. MD explicitly models each 
atom in the system as a charged point-mass whose interactions with other atoms are 
described by classical statistical mechanics. In particular, atom movement is governed 
by Newton’s second law of motion (Equation 1.1), from which the Newtonian 
equations of motion are derived. 
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𝐹𝐹 = 𝑚𝑚𝑖𝑖𝑎𝑎𝑖𝑖   (1.1) 
A force, F, acting on an atom is related to its potential energy, U, by equation 1.2. 
Therefore, equation 1.1 and 1.2 can be combined to allow an atom’s movement to be 
computed from its potential energy (Equation 1.3). 
𝐹𝐹 =  − 𝜕𝜕
𝜕𝜕𝑟𝑟𝑖𝑖
𝑈𝑈   (1.2) 
𝑚𝑚𝑖𝑖𝑎𝑎𝑖𝑖 =  −
𝜕𝜕
𝜕𝜕𝑟𝑟𝑖𝑖
𝑈𝑈             (1.3) 
The potential energy for each atom is calculated as a sum of energy terms 
corresponding to its bonded interactions and non-bonded electrostatic contributions 
(Equation 1.4). The specific combination of equations and constants used to represent 
this potential energy is termed a force field. A force field aims to produce MD 
simulations that closely match the behavior of a target set of data (typically quantum 
mechanical or empirical data). The publications presented in this thesis make use of 
the CHARMM 36 all-atom parameter set,31, 32 parameterized against quantum 
mechanical calculations, with force field equations defined within the NAMD 
software.33 
𝑈𝑈𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 = 𝑈𝑈𝑏𝑏𝑡𝑡𝑏𝑏𝑏𝑏 +  𝑈𝑈𝑡𝑡𝑏𝑏𝑎𝑎𝑡𝑡𝑎𝑎 + 𝑈𝑈𝑏𝑏𝑖𝑖ℎ𝑎𝑎𝑏𝑏𝑟𝑟𝑡𝑡𝑡𝑡 + 𝑈𝑈𝑈𝑈𝑟𝑟𝑎𝑎𝑈𝑈−𝐵𝐵𝑟𝑟𝑡𝑡𝑏𝑏𝑡𝑡𝑎𝑎𝑈𝑈 + 𝑈𝑈𝑣𝑣𝑏𝑏𝑣𝑣 +  𝑈𝑈𝐶𝐶𝑡𝑡𝐶𝐶𝑡𝑡𝑡𝑡𝐶𝐶𝑏𝑏 (1.4) 
In general, a MD simulation produces a time-dependent trajectory by iterating through 
the cycle calculations in the cycle indicated in Fig. 1.1. First, the total potential energy 
is calculated for each atom in the system (according to Equation 1.4), which is then 
related to a net force acting on that atom. This net force updates the corresponding 
velocity and acceleration for each atom. Each atom is then moved according to 
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Newton’s equations of motion over a pre-defined time step and this process is 
repeated until the desired simulation length is reached.  
A simulation can approximate the time-dependent motion of each atom in the system, 
provided the time step is chosen to be sufficiently less than the smallest molecular 
motions. The smallest molecular movements are bond length vibrations that occur on 
the order of ~10 femtoseconds (10 x 10-15 s)34 and, thus, a timestep on the order of 1 
femtosecond is typically chosen for MD simulations. Therefore, a microsecond-length 
simulation requires 1 billion (1 x 109) iterations of this algorithm and also scales 
exponentially with system size due to the n-body nature of electrostatic potential 
calculations. Understandably, this is time intensive to compute - even a supercomputer 
with algorithmic optimizations can take months to complete a single simulation.  
A key question to then consider is: at what point is the simulation length deemed long 
enough in order to draw meaningful conclusions from the data? Grossfield et. al. 
acknowledges the difficulty in addressing this question as all simulations have inherent 
Figure 1.1: Iterative calculation to compute molecular dynamics simulations. 
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statistical uncertainty and, therefore, can never be considered absolutely converged.35 
Compounding the issue, no amount of analysis can reveal whether an important 
conformation remains unvisited in a simulation unless the conformation is already 
known by other means. However, several visual and qualitative techniques can be 
used to assess whether a simulation has not run long enough and can build confidence 
in the final data set.  
In this work, we inspected plots of various metrics as time series (root-mean-square 
deviation, end-to-end distance and torsion angles) to ensure that simulations were not 
terminated whilst exploring novel conformations and that dominant conformations 
had been sampled multiple times. Further, potential of mean force (PMF) plots for 
each disaccharide linkage had been calculated prior to each simulation and the low-
energy regions could be compared against the trajectory values. Significant differences 
in conformational occupancies could be used to indicate the extent of overall sampling 
or otherwise highlight conformational aspects requiring further investigation. 
Furthermore, the methodology employed here of comparative study between related 
glycans under identical modeling parameters provides insight into relative 
conformational differences and, therefore, partially mitigates the impact of absolute 
simulation length.  
At the time of publication of the initial two journal articles in this dissertation, the N. 
meningitidis simulations studied were the longest computationally feasible data sets to 
compute and employed predominantly qualitative assessment of the conformational 
sampling. For the S. flexneri serogroups in the final two publications, additional 
statistical quantitative methods were employed in the form of block averaging analysis 
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to build further confidence in the conformational sampling. Provided that simulations 
of a reasonable length can be feasibly calculated, a comparative study of the dynamic 
motion of modeled polysaccharides can confidently rationalize and potentially predict 
cross-protection phenomena based on conformational arguments.  
1.3 Computational methodology 
This work employs an incremental systematic approach toward the computational 
study of closely related glycan antigens. First, we calculate the preferred glycosidic 
linkage orientations of each disaccharide fragment in the glycan antigen. These are 
determined by computing the potential of mean force of rotation about the linkage 
torsion angles (φ and ψ) with a metadynamics routine.36 The resulting Ramachandran-
like contour plot identifies favorable low-energy linkage conformations. 
Next, short glycan chains (6-12 sugar residues) are built with linkage conformations 
corresponding to the energy minima identified from the PMF calculations. MD 
simulations are then performed on the solvated short-chains to identify favored 
backbone conformations in solution. 
Finally, longer polysaccharide chains are built from the most favored linkage 
conformations in the short-chain MD simulations. MD simulations for the long 
polysaccharide chains are then run for a long simulation length (typically a 
microsecond) to obtain a data set or “production run” that approximates the native 
backbone conformations. The final data sets can be probed for convergence and 
extended if needed. Broad insights are gleaned from the glycan simulations by plotting 
the time trajectories of the end-to-end distances as well as scatter plots of the linkage 
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torsion angles. Clustering analysis is employed to determine and compare the 
dominant chain conformations. The research here is conducted in the format of 
comparative study between antigens that are treated under identical modeling 
conditions. This reveals the relative differences in conformational behavior between 
polysaccharide antigens as induced by small structural alterations in their respective 
RUs.  
1.4 Aims 
This dissertation includes four journal articles that aid the development of optimized 
vaccines for diseases that are particularly prevalent in LMICs on the African continent 
and further detailed literature is included within each publication. The first two papers 
investigate potential antigens for use in next-generation multivalent vaccines against 
Neisseria meningitidis (meningococcal) infection. The next two papers focus on 
computational modeling of candidate vaccine serotypes to prevent diarrheal disease 
caused by Shigella flexneri infection and explore the potential cross-protection of a 
proposed multivalent vaccine. 
The dissertation therefore takes the form of a set of case studies that rationalize 
vaccination cross-protection data if available, or otherwise provides predictive insight 
into glycan antigens to guide vaccine design. 
Therefore, this work broadly aims to contribute a part of the answer as to how 
molecular dynamics simulations of glycan antigens can be leveraged to provide key 




1.5 Dissertation structure 
This is a thesis that includes publications, as listed in Table 1.1. The first two of four 
results chapters, Chapter 2 and 3, consider the modeling of N. meningitidis 
polysaccharide antigens to guide the development of next-generation meningococcal 
vaccines. 
Chapter 2 investigates whether a meningococcal serogroup A vaccine may confer 
cross-protection against the related serogroup X and, therefore, whether a serogroup 
X component is recommended for inclusion into current multivalent vaccines in 
development. It continues by determining the effect of the O-acetylation moiety on 
the conformation of the serogroup A backbone. 
Chapter 3 analyzes the conformational differences between the native meningococcal 
serogroup A polysaccharide and a carba-analogue polysaccharide that is proposed as a 
chemically-stable alternative to current serogroup A vaccines. 
The second section of this dissertation examines the O-antigens (O-Ags) of S. flexneri 
strains, to inform current development efforts toward the first licensed Shigella 
vaccine. 
Chapter 4 investigates the conformations of serogroup 2, the dominant cause of 
shigellosis infection, and the unsubstituted serotype Y backbone. 
Chapter 5 continues by exploring serogroups 3 and 5 to glean potential cross-
protection relationships and to provide support for the composition of a proposed 
multivalent vaccine containing serotypes 2a and 3a. 
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Chapter 6 concludes the dissertation by providing an overview of the preceding 





Modeling the CPS of N. meningitidis 
serogroup A and X 
 
2.1 Foreword 
The following article “Conformations of Neisseria meningitidis serogroup A and X 
polysaccharides: the effects of chain length and O-acetylation” investigates two strains 
of the causative agent of frequent meningitis epidemics in Africa – Neisseria 
meningitidis. Past African meningococcal epidemics were predominantly due to 
serogroup A, with vaccination playing a pivotal role in controlling the disease burden. 
The affordable serogroup A vaccine developed for Africa (MenAfriVac) was deployed in 
mass vaccination campaigns from 2010, which subsequently nearly eliminated 
serogroup A infection in vaccinated populations. However, infection by the chemically 
similar serogroup X remained, indicating a lack of conferred cross-protection from 
serogroup A and raising the question as to why this is the case. 
This study finds key conformational differences between serogroup A and X, 
rationalizing the lack of cross-protection and adding to the call for current multivalent 
vaccines to be extended to include a serogroup X component. For serogroup A, the 
partial O-acetylation on the bacterial CPS is known to be important for antibody 
recognition but without a clear understanding of any potential structural changes. This 
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study reveals a chain-straightening effect of the O-acetyl moiety, which provides a 
rationale for the reported immunogenic differences between O-acetylated and de-O-
acetylated chains. The finding supports the required O-acetylation of serogroup A 
vaccines by vaccine regulatory agencies and provides further understanding of 
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Neisseria meningitidis is a major cause of bacterial meningitis worldwide especially in 
Africa. The capsular polysaccharide (CPS) is the main virulence factor and the target 
antigen for polysaccharide and conjugate vaccines. The high burden of serogroup A 
disease in the Meningitis Belt of sub-Saharan Africa led to the introduction of 
MenAfriVac®, which has successfully reduced the number of cases of group A disease. 
However, several outbreaks caused by other serogroups have been reported, including 
those due to serogroup X. The capsular polysaccharides of serogroups A and X are both 
homopolymers of amino sugars (α-D-ManNAc and α-D-GlcNAc) containing 
phosphodiester linkages at C-6 and C-4, respectively. The similarity of the primary 
structures of the two polysaccharides suggests that serogroup A vaccination may 
provide cross-protection against serogroup X disease. Molecular dynamics simulations 
of a series of serogroup A and X oligosaccharides reveal that the MenA CPS behaves as 
a flexible random coil which becomes less conformationally defined as the length 
increases, whereas serogroup X forms a more stable regular helical structure. The 
presence of the MenX helix is supported by NMR analysis; it has four residues per turn 
and becomes more stable as the chain length increases. Licensed MenA vaccines are 
largely O-acetylated at C-3: simulations show that these O-acetyl groups are highly 
solvent exposed and their presence favors more extended conformations compared to 
the more compact conformations of MenA without O-acetylation. These findings may 
have implications for the design of optimal conjugate vaccines. 





The encapsulated bacterium Neisseria meningitidis is the causative agent of 
meningococcal disease, which results in meningitis, septicemia, and pneumonia. 
Humans are the only known host of N. meningitidis, which asymptomatically inhabits 
the nasopharynx of approximately 10% of the general population during non-epidemic 
periods and with varying serogroup distribution by geographic region.37 
Meningococcus is easily spread through respiratory droplets; thereafter infection 
occurs if the bacteria cross the mucosal membranes into the blood stream.38 If left 
untreated, meningococcal disease has a high mortality rate.39 Meningitis epidemics 
occur regularly on the African continent in an area extending from Senegal to Ethiopia, 
termed “the Meningitis Belt”.40, 41  
The bacterial capsular polysaccharide (CPS) of meningococcus is the main virulence 
factor and vaccination with the CPS is an effective method of limiting the spread of the 
disease.42 The first successful vaccines against N. meningitidis infection were 
polysaccharide vaccines developed in the 1970s43, 44 which are being replaced by the 
more immunogenic polysaccharide-protein tetravalent conjugate vaccines (Menactra, 
Menveo, and Nimenrix) that are more effective in children.45 
The N. meningitidis CPS is used to categorize the bacteria into twelve serogroups, of 
which six (A, B, C, W, X and Y) cause virtually all meningococcal disease worldwide. 
Prior to vaccination, over 90% of meningococcal disease in the Meningitis Belt was 
caused by serogroup A (MenA). After introduction of a cost-effective MenA conjugate 
vaccine (MenAfriVac®, developed by the Meningitis Vaccine Project)46 in 2010, MenA 
infections have been virtually eliminated in vaccinated populations.47-50 However, 
32 
 
recent outbreaks of serogroup X (MenX) disease42, 51 suggest the possibility of 
replacement of serogroup A by MenX.48-52 This has prompted the development of a 
new pentavalent conjugate vaccine (NmCV-5) against serogroups A, C, Y, W, and X.53 
The CPS of the meningococcal serogroups fall into three structurally related pairs: CPSs 
of serogroup A and X are phosphodiester-linked homopolymers of hexose amino 
sugars, serogroup B and C are homopolymers of sialic acid, and serogroup Y and W are 
polymers of hexose-sialic acid, as listed below.  
A:  ⇾6)-α-D-ManpNAc(3/4OAc)-(1⇾OPO3 ⇾ 
X:  ⇾4)-α-D-GlcpNAc-(1⇾OPO3 ⇾ 
B:  ⇾8)-α-D-NeupNAc-(2⇾ 
C: ⇾9)-α-D-NeupNAc(7/8OAc)-(2⇾ 
Y:  ⇾6)-α-D-Glcp-(1⇾4)-α-D-NeupNAc(7/9OAc)-(2⇾ 
W:  ⇾6)-α-D-Galp-(1⇾4)-α-D-NeupNAc(7/9OAc)-(2⇾ 
The focus of this study is on the MenA and MenX pair, which differ in their linkage 
position (4-linked in MenX and 6-linked in MenA) and are epimeric at the C-2 position: 
the N-acetyl group is axial in MenA (manno) and equatorial in MenX (gluco). 
Furthermore, the MenA CPS is O-acetylated predominantly at C-3 (70 to 95%) with low 
levels at C-4. O-acetylation is considered to be important for immunogenicity54 and 
WHO guidelines recommend that MenA vaccines have at least 61.5% O-acetylation.55  
Oligosaccharide length is an important consideration for the development of synthetic 
conjugate vaccines:56 the oligosaccharide used must be sufficiently long to be 
representative of the CPS conformation, but short enough for synthesis to be practical. 
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For the synthetic MenX vaccine in particular, it is important to determine the minimal 
epitope of the saccharide required for immunological activity against the MenX CPS.57 
However, there is limited data on the oligosaccharide length necessary for an 
immunogenic MenA and MenX glycoconjugate. A trimer of a carba-sugar analogue of 
MenA elicited a poor immune response in mice in comparison to oligosaccharides of 6 
to 15 RU.58 However, a MenA tetramer conjugate was shown to be antigenic in a 
competitive inhibition assay with rabbit antisera, although immunogenicity is still to be 
proven.59 Fiebig et. al. showed that an average degree of polymerization of 10 units 
(avDP10) MenA conjugate had similar immunogenicity in mice as compared to the 
avDP15 standard.60 For MenX, Morelli et al. synthesized monomer, dimer, and trimer 
glycoconjugates and found that only the trimer was able to induce IgG antibodies 
against MenX CPS, however, this was at low levels in comparison to the avDP15 MenX 
control that induced a large antibody response.57 Although many variables affect the 
immunogenicity of conjugate vaccines, it is not clear what the minimum repeating unit 
(RU) length should be for MenA and MenX oligosaccharide-based vaccines.  
Vaccine efficacy data indicates that the chemical structural similarity of bacterial CPSs 
alone is not able to reliably predict cross-protection between closely related strains.26, 
61, 62 Small changes in a glycan structure can lead to large changes in conformation and 
dynamics and thus affect antigen binding and immunogenicity. Experimental 
techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy are only able to provide partial insights into glycan conformation,63, 64 
whereas computational methods can provide key theoretical insights into 
polysaccharide conformation. In particular, molecular dynamics (MD) simulations 
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provide atomistic information on dynamic polysaccharide motion in solution on the 
nanosecond timescale that is inaccessible to physical experiments. MD is a powerful 
predictor of glycan conformation which can be used to compare related antigenic 
glycans: our recent work on N. meningitidis serogroups Y and W demonstrated key 
conformational differences that provide a rationale for the unusual cross-reactivity 
observed.27  
Here we employ MD simulations to explore the conformational preferences of MenA 
and MenX oligosaccharides. Our established methodology25, 65 employs an incremental 
approach whereby we first simulate the respective disaccharide repeating units in 
order to determine the preferred individual linkage conformations. As saccharide rings 
are relatively rigid structures, the conformations of oligosaccharide chains are 
primarily determined by the torsion angles in these glycosidic linkages. The preferred 
torsion values are then used to build longer oligomers for MD simulation in order to 
generate predictions of the conformation of the CPS. We simulate 2, 6, and 10 
repeating units (RU) to determine the effect of chain length, considered an important 
factor for the immunogenicity of glycoconjugate vaccines.66, 67 Evaluation of predicted 
structures is primarily performed by cluster analysis which provides insight into the 
relative preference of the polymer for particular conformations. The conformational 
clusters can be compared between structurally similar repeating units of different 
saccharides to determine the extent of the role that CPS conformation plays in 
explaining observed immunological cross-reactivity. We use NMR NOESY correlations 
as corroboration for the predicted conformations. Lastly, we model MenA with 3-O-
acetylation to observe the effect of this substituent on CPS conformation.  
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2.4 Results and discussion 
In the discussion below, we first present the conformations of de-O-acetylated MenA, 
then MenX, and finally the effect of 3-O-acetylation on MenA. For each serogroup, we 
first discuss the linkage conformations [->6)-α-D-ManpNAc-(1->OPO3-> for MenA and   
->4)-α-D-GlcpNAc-(1->OPO3-> for MenX] and then move on to conformational analysis 
of the 2 RU, 6 RU, and 10 RU oligomers. In the case of MenX, NMR evidence is used to 
corroborate our findings.  
2.4.1 MenA CPS backbone conformation 
The flexible α(1⇾6) linkage in MenA is described by five torsion angles: φ, ψ, ω, ε and 
χ (shown on a representative disaccharide linkage in Fig. 2.1a and 2.1b). The torsion 
angle time series from the 400 ns simulation of 6 RU of MenA (Fig. 2.1c) shows that 
these torsion angles vary in flexibility. The φ and ε torsion angles are the least flexible, 
each having a single conformation with average values of φ = 341° and ε = 179°, 
respectively. The χ primary alcohol torsion angle is constrained, with only brief 
transitions away from the primary gg conformation (χ = 174°). In contrast, the two C-
O-P-O torsion angles (ψ and ω) are much more flexible and have strongly correlated 
motion in the 6 RU MenA simulation with transitions between two main 
conformations: a primary conformation with ψ, ω ≈ 77°,77° and a secondary 
conformation with ψ, ω ≈ 273°, 282° (Fig. 2.1c). The primary linkage torsion angle 
orients the adjacent sugar ring in an extended conformation (Fig. 2.1a), whereas the 
secondary conformation results in a hairpin bend conformation around the 
phosphodiester linkage (Fig. 2.1b).  
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Figure 2.1. Torsion angles for the α(1⇾6) linkage in MenA (left column) and the α(1⇾4) 
linkage in MenX (right column). For MenA, there are two primary conformations: (a) an 
extended linkage conformation with φ, ψ, ω, ε, χ = 334°, 77°, 77°, 181°, 152° and (b) a 
hairpin bend with φ, ψ, ω, ε, χ = 325°, 271°, 282°, 178°, 174°. The corresponding torsion 
angle time series plots for the central linkage in a 6 RU MenA strand over the 400 ns 
simulation trajectory are shown in (c). The four bond linkage in MenX has a single 
preferred conformation with torsion angles of φ, ψ, ω, ε = 333°, 271°, 262°, 181° (d). 
The corresponding torsion angle time series plots for the central linkage in a 6 RU 
MenX strand over the 300 ns simulation trajectory are shown in (e).  
37 
 
As conformational changes of the α(1⇾6) linkage occur predominantly due to 
transitions in ψ and ω, we simplify the conformational preferences of the α(1⇾6) 
linkage in our simulations of 2 RU, 6 RU and 10 RU oligosaccharide strands with plots 
of the ψ vs ω torsion angles only. The glycosidic linkage in the 2 RU strand is 
predominantly in the hairpin bend conformation (ψ, ω ≈ 274°, 283°, Fig. 2.2a), with a 
second major population of the extended conformation (ψ, ω ≈ 77°,78°). Upon 
increasing the length of the oligosaccharide strand, the conformational preferences 
shift so that 6 RU (Fig. 2.2b) has an approximately equal weighting of hairpin bends 
and extended conformations, as well as a range of intermediate conformations. For 
the 10 RU simulation (Fig. 2.2c), the extended conformation population increases, as 
does the population of intermediate conformations. As repeating unit length changes, 
the conformational preferences of the MenA α(1⇾6) linkages change, therefore, the 
conformations of very short chains are not likely to be representative of the behavior 
of the native MenA CPS.  
Our simulations reveal that the MenA CPS is a highly dynamic random coil with no 
regular conformational epitope. Clustering of the last 250 ns of the 400 ns MenA 6 RU 
simulation reveals a wide range of conformational families, as shown in Fig. 2.3. The 6 
RU chain switches dynamically between compact (Fig. 2.3, A1, 33%), extended (Fig. 2.3, 
A2, 16%) and a variety of intermediate conformations (Fig. 2.3, A3, A4 and A5). This 
behavior of the MenA oligosaccharide correlates with reported 3J 31P-13C coupling 
values that suggest a preference for extended anti conformations for the φ and ε 




Figure 2.2. Scatter plots of the glycosidic linkage ψ, ω time series in the last 250 ns of 
the simulation trajectories for the α(1⇾6) linkages in MenA (left column) and the last 
150 ns for the α(1⇾4) linkages in MenX (right column). For MenA, the range of motion 
of the glycosidic linkages increases as the chains grow in length from (a) 2 RU, to (b) 6 
RU, and (c) 10 RU. In contrast, for MenX the glycosidic linkages decrease in mobility 
from (d) 2 RU, to (e) 6 RU, and (f) 10 RU. (Note that, for both 6 RU and 10 RU, the plots 
for the three central linkages in the strands are superimposed.) 
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2.4.2 MenX conformation 
The α(1⇾4) linkage in MenX is described by four torsion angles: φ, ψ, ω and ε (shown 
on a representative disaccharide linkage in Fig. 2.1d). The torsion angle time series 
from the 250 ns simulation of 6 RU of MenX (Fig. 2.1e) shows that, as for MenA, these 
torsion angles vary in flexibility. This simulation was initialized with the dominant 
conformation from the 2 RU simulation: φ, ψ, ω, ε = 355°, 70°, 70°, 185°, but after 
equilibration for 80 ns, the ψ, ω, ε torsion angles rotated to a stable conformation of 
this linkage with average values of φ, ψ, ω, ε ≈ 320°, 270°, 265°, 340°. The φ torsion 
angle alone remained near the initial conformation. The fact that a significant 
conformational transition for the 6 RU strand took place only after 80 ns of 
equilibration illustrates the need to ensure that polysaccharide simulations are long 
enough to ensure thorough conformational sampling of the torsion angles; we have 
noted similar long equilibration times were required for simulations of 6 RU of the 
MenW saccharide.27 
In contrast to MenA, the conformation of the glycosidic linkage in MenX becomes 
more stable as the chain length increases from 2 RU to 6 RU and 10 RU, as is clear from 
the scatterplots of the ψ vs ω torsion angles for the last 150 ns of MenX simulations 
shown in Fig. 2.2 (right column). For the 2 RU strand (Fig. 2.2d), the glycosidic linkage 
rotates regularly between two dominant conformations, with ψ, ω ≈ 95°, 100° and ψ, 
ω ≈ 270°, 265°, respectively. Upon increasing the chain length to 6 RU, the range of 
motion of the middle linkage (Fig. 2.2e) is clearly more constrained, showing a clear 
preference for the ψ, ω ≈ 270°, 265° conformation. The 10 RU simulation was begun 




Figure 2.3. Conformational families and relative populations for 6 RU of MenA (green, 
left) and MenX (blue, right). 
ψ, ω ≈ 95°, 100° throughout the course of the 250 ns run (Fig. 2.2f). This 
conformational dependence of chain length provides a rationalization for the finding 
that oligomers longer than 3 RU are required for immunological activity against the 
MenX CPS.57  
Clustering of the MenX 6 RU trajectory conformations show that the dominant stable 
glycosidic linkage conformation (φ, ψ, ω, ε ≈ 320°, 270°, 265°, 340°) corresponds to a 
helix with four residues per turn (Fig. 2.3, X1). Comparison of the 6 RU and 10 RU 
simulations suggests that this helical conformation becomes more stable as the chain 
length increases: the 6 RU strand was in a helical conformation for 88% of the final  
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Figure 2.4: (a) Labelled expansion overlay of the 1D NOESY and 1H spectra for MenX 
obtained from selective irradiation of H-6, showing a strong correlation to H-3. The 
double correlation from H-6 to H-3 of one- and two RU along the polysaccharide is 
shown on the 3D model (b) as well as diagrammatically (c). 
250 ns of the 6 RU simulation, whereas the 10 RU strand showed a helical 
conformation throughout the 250 ns run. 
This hypothesis of a helical conformation of the MenX CPS is supported by key NMR 
NOEs obtained from 1D NOESY experiments. Differentiating between NOE correlations 
arising from intra-residue and inter-residue interactions for a homopolymer such as 
MenX is challenging because the atoms H-1 to H-6 are in the same chemical 
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environment for every residue. A NOESY correlation between a proton pair will have 
an identical chemical shift whether the correlation occurred due to intra-residue or 
inter-residue magnetization transfer and these are indistinguishable by NMR. 
Therefore, an inter-residue NOE can only be assumed where an intra-residue NOE is 
not possible. 
A selective 1D NOESY experiment with irradiation of H-6 showed a strong correlation 
to H-3, indicating that H-6 and H-3 are in close proximity (Fig. 2.4a). As H-3 is on the 
opposite side of the GlcNAc ring to H-6 and NOE correlations to H-6 are weak for the 
remaining ring protons, this correlation must arise from close inter-residue contact. 
Indeed, the helical conformation predicted by our simulations brings H-6 into close 
proximity with H-3 from both the n+1 and n+2 RU (Fig. 2.4b and 2.4c). The NOESY 
correlation detected between H-6 and H-3 is thus strong evidence for a helical 
conformation of the MenX CPS.  
Another inter-residue NOE correlation observed is also compatible with a helical 
conformation. A low intensity NOE correlation between H-6 and the NAc methyl 
detected again cannot be explained by an intra-residue NOE correlation because of the 
large distance between these groups (~9 Å). However, in the simulations, each NAc 
group was regularly in close proximity to the C-6 methyl on the sugar ring two RU 
along the polysaccharide chain (Suppl. Fig. S2.1).  
2.4.3 Conformation of O-acetylated MenA 
O-acetylation, 70 to 95% at C-3, is known to be important for the immunogenicity of 




Figure 2.5: Conformational families with relative percentages for the 6 RU simulations 
of (a) MenA and (b) O-acetylated MenA (with acetyl groups colored in red). Time series 
of the end-to-end distances over the 400 ns simulations are shown for (c) MenA and (d) 
O-acetylated MenA; the dashed blue line indicates the point at which clustering 
analysis starts. Scatterplots show the ψ vs ω torsion angles for the superimposed 
central three linkages over the final 150 ns for (e) MenA and (f) O-acetylated MenA.  
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that this has an effect on the conformation of the MenA backbone. While the O-
acetylated MenA has a similar family of conformations as compared to the de-O-Ac 
MenA, the distribution of these conformations is distinctly different. O-acetylation 
shifts the conformational preferences of MenA from a compact conformation (Fig. 
2.5a, A1) to an extended conformation (Fig. 2.5b, Ac1): when O-acetylated, a 6 RU 
strand is in an extended conformation for 50% the simulation time, as opposed to only 
16% for the de-OAc MenA 6 RU (Fig. 2.5a, A2). Therefore, 6 RU of O-acetylated MenA 
is more conformationally defined than its de-O-acetylated counterpart. This provides a 
rationale for the low serum bactericidal titers observed after immunization with a de-
O-acetylated vaccine candidate54 as the de-O-acetylated MenA chain does not 
adequately mimic the native MenA chain conformation. In contrast to MenX, a series 
of NOESY experiments performed on O-acetylated MenA only gave intra-residue 
correlations. 
The increase in the extension of the 6 RU chain upon O-acetylation is apparent in a 
comparison of the time series graphs of the molecular end-to-end distance over time 
of the O-acetylated chain (compare Fig. 2.5c and Fig. 2.5d). The increased extension 
arises from a shift in the orientation of the α(1⇾6) linkage away from hairpin bends 
(ψ, ω ≈ 280°, 290°) towards a more extended conformation (ψ, ω ≈ 75°, 80°), as is 
clear in the scatterplot for MenA (Fig. 2.5e) and O-acetylated MenA (Fig. 2.5f). In the 
O-acetylated 6 RU oligomer, hairpin bend conformations persist for shorter periods of 
time. The O-acetylated MenA also has somewhat more frequent rotations around the 
χ torsion angle as compared to the de-O-acetylated chain.  
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A final observation is that the O-acetyl groups (colored red in Fig. 2.5b) in all 
conformational families are highly solvent exposed and therefore expected to make 
significant alterations to the hydrophilicity of the O-acetylated CPS surface as 
compared to the de-O-acetylated MenA. This altered surface for antibody binding 
together with the shift in conformational preferences on O-acetylation suggests that 
the de-O-acetylated MenA is likely to offer at most limited cross-protection against the 
O-acetylated native MenA CPS, thereby explaining why O-acetylation is important for 
MenA vaccines.  
2.5 Conclusions 
Comparison of the MenA and MenX simulations shows that the flexible five-bond 
α(1⇾6) glycosidic linkage in MenA produces a markedly more disorganized saccharide 
chain than the α(1⇾4) linkage in MenX: the 6 RU MenA oligosaccharide behaves as a 
random coil in aqueous solution, whereas 6 RU of the MenX CPS forms a regular helix. 
The helical model for MenX is corroborated by evidence from selected NMR NOESY 
NOEs. The conformation of the MenX oligosaccharide is length dependent, with the 
helical conformation becoming increasingly stable as the chain length increases from 2 
RU to 10 RU. As the stable helix conformation has four residues per turn, our 
simulations suggest that the minimal epitope required for the immunological activity 
against the MenX CPS will be at least 4 RUs. The large difference in structure and 
conformation between MenA and MenX provides a rationale as to why no cross-
protection against MenX infection from MenA vaccination is observed, thereby 
validating the need for a MenX vaccine. 
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In addition, our simulations reveal that O-acetylation has an effect on the 
conformation of the MenA saccharide chain: O-acetylation favors extended 
conformations over more compact conformations with hairpin bends of the α(1⇾6) 
glycosidic linkage. This conformational difference, together with the fact that the O-
acetyls are highly solvent exposed, may explain why O-acetylation is important for 
MenA vaccines.  
2.6 Experimental 
We analyzed the MenA and MenX saccharides according to the glycosidic linkage 
torsion angles. For the five-bond α(1⇾6) phosphodiester linkage of MenA the torsion 
angles are here defined as: φ = H1-C1-O1-P, ψ = C1-O1-P-O6’, ω = O1-P-O6’-C6’, ε = P-
O6’-C6’-C5’ and χ = O6’-C6’-C5’-H5’. The four-bond α(1⇾4) phosphodiester linkage in 
MenX has torsion angles defined similarly as φ = H1-C1-O1-P, ψ = C1-O1-P-O4’, ω = O1-
P-O4’-C4’, ε = P-O4’-C4’-H4’.  
2.6.1 Molecular dynamics simulations 
All simulations were performed with the NAMD molecular dynamics program33 with 
CUDA extensions to enable calculation of long-range electrostatic forces and non-
bonded forces on graphics processing units.69 Glycans were modeled with the 
CHARMM36 additive force field for carbohydrates,31, 32 incorporating ad hoc 
extensions to represent the phosphodiester linkages and the acetyl substituents. 
Water was simulated with the TIP3P water model,70 which is compatible with the 
CHARMM carbohydrate force field.  
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The initial structures for simulations were in all cases built using our in-house software 
CarbBuilder,71, 72 which employs the psfgen tool to create Protein Structure Files (PSF) 
for modeling with the CHARMM force field in the NAMD molecular dynamics program. 
Structures for the 6 RU oligosaccharides were built using the most common torsion 
angles from the respective 2 RU simulations, and the 10 RU simulations similarly used 
the most common values from the 6 RU simulations. All simulations began with 10,000 
steps of standard NAMD minimization in vacuum followed by solvation in a water box 
using the solvate routine in the Visual Molecular Dynamics (VMD) software.73 To 
reduce computational cost, a minimal water box size was chosen for each simulation 
whilst still sufficiently enveloping the respective chains: the 2 RU and 6 RU simulations 
used a 60 Å3 periodic cubic cell (approximately 7,000 water molecules) and the 10 RU 
structures had 80 Å3 for MenA 10 RU and 70 Å3 for MenX 10 RU (16,000 and 11,000 
water molecules respectively). This variation in water box size implies a difference in 
effective solute concentration that may be relevant in expanded study into 
interactions between multiple chains or of the chain with salt ions. Randomly-
distributed sodium ions were added to each system using the VMD autoionize feature 
in order to electrostatically neutralize the negative charge from the phosphodiester 
linkages.  
All MD simulations were preceded by a 122,000 step minimization and heating phase, 
consisting of 5 K temperature reassignments from 10 K to a maximum temperature of 
310 K with 1,000 steps of minimization and 1,000 steps of MD at each temperature. 
The 2 RU MenA and MenX simulations and the 6 RU MenX simulation ran for 300 ns 
whereas, in order to allow for equilibration, the highly flexible MenA and MenA-3Ac 6 
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RU simulations were run for 400 ns. The 10 RU simulations are computationally 
expensive and so were only run for 250 ns. While this was not sufficient for full 
conformational equilibration, this allowed us to probe the conformational preferences 
of these longer strands. 
For the MD, equations of motion were integrated using a Leap-Frog Verlet integrator 
with a step size of 1 fs and periodic boundary conditions. Simulations were performed 
under isothermal-isobaric (nPT) conditions at 310 K maintained using a Langevin piston 
barostat33 and the Nose-Hoover thermostat implemented in NAMD, which is a 
combination of a Nose-Hoover constant pressure method74 with piston fluctuation 
control implemented using Langevin dynamics.75 Long-range electrostatic interactions 
were treated with particle mesh Ewald (PME)76 summation using k = 0.20 A-1 and PME 
grid dimensions equal to the system periodic cell dimensions. Non-bonded interactions 
were truncated with a switching function applied between 12.0 and 15.0 Å. The 1-4 
interactions were not scaled, in accordance with CHARMM force field 
recommendations.  
2.6.2 Post-simulation analysis 
Molecular structures were visualized with VMD,73 where necessary using the 
PaperChain visualization algorithms77 to highlight the glycan rings.  
For each simulation trajectory, a time series of molecular conformations spaced 12.5 
ps apart was extracted for analysis. Analysis of the ψ and ω torsion angles used only 
the final 150 ns of each simulation. For the 6 RU and 10 RU saccharides, the ψ and ω 
scatter plots combined the time series from the three middle glycosidic linkages in the 
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chains. End-to-end distances for the 6 RU saccharide chains were defined to exclude 
the terminal residues, from C-1 of residue 2 to C-4 of residue 5. 
For clustering, the 6 RU simulation conformations were aligned on the middle 2 RU 
and then clustered into conformational families using VMD’s internal cluster 
command, which applies the quality threshold algorithm.78 The clustering metric 
comprised an RMSD fit of the saccharide backbone for the middle 4 RU in the 6 RU 
strand (where the backbone is defined as the glycan ring carbon and oxygen atoms, as 
well as the oxygen and phosphorous atoms in the glycosidic linkages) with a cut-off 
value of 3.5 Å. The first 150 ns of each simulation were treated as equilibration and not 
clustered.  
Theoretical 3J 31P-13C coupling values for comparison with NMR literature were 
calculated using a Karplus equation parameterized for 31P-O-C-13C torsion angles.79 
2.6.3 NMR analysis 
MenA and MenX polysaccharide samples (~10 mg) were lyophilized and exchanged 
twice with 99.9% deuterium oxide, then dissolved in 600 μL of D2O and introduced 
into a 5 mm NMR tube for data acquisition. MenA and MenX polysaccharide samples 
(~10 mg) were lyophilized and exchanged twice with 99.9% deuterium oxide (D2O), 
then dissolved in 600 μL of D2O and introduced into a 5 mm NMR tube for data 
acquisition. 1H, 1D selective NOESY (selnogp) and 2D NOESY (noesyphpr) spectra were 
recorded using a range of mixing times (100 to 300 ms for MenA and 100 to 400 ms for 
MenX, D1 of 2s) on a Bruker Advance III 600 MHz NMR spectrometer. For the 1D 
NOESY, the isolated H6 peak was selected by integration and subsequently irradiated 
with a band width of 100 Hz. The spectrometer was equipped with a BBO Prodigy 
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cryoprobe set at a temperature of 303 K and NMR spectra were processed using 
standard Bruker software (Topspin 3.2).  
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2.7 Supplementary information 
 
 
Figure S2.1: Left panel: 3D helical model of MenX showing H-6 to NAc methyl group 
distances that illustrates the inter-residue NOE observed (left panel). Right panel: The 
relatively rigid intra-residue H-6 and NAc methyl group distance is consistently longer 
than the ~5 Å limit for NOE correlations (blue). However, the inter-residue distance of 
H-6 and the NAc methyl group of the residue two RU away (red) is regularly within this 






Analysis of a chemically-stable mimic of N. 
meningitidis serogroup A 
 
3.1 Foreword 
The following article “Comparison of the conformation of Neisseria meningitidis 
serogroup A CPS with a carba-analogue: implications for vaccine development” extends 
the study of meningococcal serogroup A. The CPS of serogroup A is chemically-labile, 
which limits shelf-life and requires a two-vial presentation that increases storage and 
transportation costs. A proposed solution is to stabilize the glycosidic linkages by 
synthetically replacing the electron-withdrawing ring-oxygen with a methylene group, 
however, it is unclear how this might impact overall polysaccharide conformation.  
 
The study finds key conformational differences between the native CPS and the carba-
analogue chain, suggesting limited cross-protection from the proposed replacement 
stable analogue. This publication also notes significant differences between the 
conformations of short glycan chains and the corresponding longer chains. Indeed, this 
variance in immune response has been observed in clinical study of MenA antigens 
where no bactericidal activity was detected in mice immunized with a 1 RU or 2 RU 
Carba-MenA glycoconjugate, while a moderate response was observed in mice 
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immunized with a 3 RU Carba-MenA glycoconjugate.58 However, the same study found 
significant antibody responses for longer 6 RU and 15 RU native MenA 
glycoconjugates. These findings highlight a need for caution when selecting antigen 
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Neisseria meningitidis is a major cause of bacterial meningitis worldwide, especially in 
Africa. The capsular polysaccharide is the main virulence factor and the target antigen 
for polysaccharide- and conjugate vaccines. Three tetravalent conjugate vaccines 
against serogroups A, C, Y and W have been licensed and the monovalent MenAfriVac® 
was introduced to address the high burden of serogroup A disease in the Meningitis 
Belt of sub-Saharan Africa. Three of these four vaccines are lyophilized due to the 
instability of the serogroup A antigen (MenA) in aqueous solution, resulting in a two-
vial presentation with concomitant additional costs for storage and distribution. 
Replacement of the saccharide ring oxygen with a methylene group is a promising 
approach to preparing a stable oligosaccharide MenA analogue (Carba-MenA) vaccine 
suitable for a liquid formulation. However, to be effective, Carba-MenA must elicit an 
immune response that is cross-reactive to the native MenA. Here we employ 
microsecond molecular dynamics simulations of ten repeats of MenA and Carba-MenA 
to establish that there are significant differences in the conformation and dynamics of 
these antigens in solution. Carba-MenA has a more random extended, conformation 
than MenA; MenA has a significant population of compact S-bend conformations that 
are absent in the analogue. We also find that the disaccharides are poor models of the 
conformational behavior of longer chains. This information is relevant for the rational 
design of optimal analogues for conjugate vaccines.  
 
Keywords: Neisseria meningitidis, Serogroup A, capsular polysaccharide, carba-




Meningitis and septicemia caused by the encapsulated bacterium Neisseria 
meningitidis has significant morbidity and mortality in children and young adults 
worldwide. There are twelve known serogroups of N. meningitidis, six of which - A, B, 
C, W, X, and Y - are associated with epidemic infection. Meningococcal epidemics have 
occurred regularly in the “Meningitis Belt” region of sub-Saharan Africa, reaching from 
Senegal to Ethiopia.40 The meningococcal capsular polysaccharide (CPS) is the primary 
virulence factor and vaccine target: vaccination with saccharide-protein conjugates has 
reduced the burden of meningococcal disease worldwide.42 
Prior to vaccination campaigns in 2010, meningococcal epidemics reached incidence 
rates of 1,000 cases per 100,000 population, of which over 90% were due to serogroup 
A (MenA) infection.80 MenA produces a homopolymeric CPS comprising an α(1→6)-
linked phosphodiester N-acetyl-D-mannosamine (Fig. 3.1a) with O-acetylation: ⇾6)-α-
D-ManpNAc(3/4OAc)-(1⇾OPO3 ⇾. The introduction of an affordable serogroup A 
vaccine (MenAfriVac®) in 201046 has virtually eliminated MenA infection in vaccinated 
populations,47-50 demonstrating the efficacy of vaccination against meningococcal 
infection. The licensed tetravalent meningococcal conjugate vaccines (Menactra®, 
MenveoTM and Nimenrix®) contain MenA together with serogroups C, Y and W. The 
instability of the MenA antigen in aqueous solution, attributed to the presence of the 
axial N-acetyl group at C2 of ManNAc,81 means that three of these four licensed 
vaccines contain MenA in the more stable lyophilized form. This requires a two-vial 





Figure 3.1: Representative disaccharide repeating units of the CPSs of (a) MenA and (b) 
Carba-MenA, showing the torsion angles defining the linkage orientations and the 
location of the phosphate. The repeating unit structures are shown below: the Carba-
MenA analogue substitutes the N-acetyl-D-mannosamine ring oxygen with a methylene 
group. 
Several approaches have been taken to the synthesis of stable MenA CPS analogues 
suitable for a liquid formulation: C-phosphonates,82, 83 a carba-sugar and, more 
recently, a triazole analogue.84-86 The most promising of these (here termed Carba-
MenA) replaces the ring oxygen of N-acetyl-D-mannosamine with a methylene group – 
compare Fig. 3.1a with Fig. 3.1b.87  
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To be an effective antigen, an analogue must elicit an immune response that is cross-
reactive with the native MenA CPS. There also is the question of chain length: for 
MenA, chains with more than four repeating units (RU) appear to provoke stronger 
antigenic responses, with optimal immunogenicity predicted for 5-7 RU.56 Harale et. al. 
reported an antigenic MenA tetramer conjugate, though immunogenicity is still to be 
proven.59 
The precise mechanisms involved in antigen cross-protection remain unclear, but it is 
generally understood that structural similarity is not sufficient to ensure cross-
protection for CPS antigens.26, 61, 62 Because small alterations in saccharide structure 
(e.g. in a residue type, linkage position, substitution, and side chains) can produce 
significant changes in molecular conformation and flexibility, conformational similarity 
of the antigens is also expected to be necessary for antigen cross-protection.1 
Molecular modeling is playing an increasingly important role in prediction of the 
conformation of flexible glycans in solution, both in combination with experiment25, 88 
and on its own.27 Recent modeling studies have predicted significant conformational 
effects resulting from O-acetylation in MenA1 and the typhoid CPS,89 as well as from 
branching as described for the O-polysaccharides of Klebsiella pneumoniae90 and 
Moraxella catarrhalis.91 In particular, comparison of the conformation and dynamics of 
MenA and Carba-MenA antigens is expected to provide insight into the viability of 
replacing the unstable MenA with a more stable analogue. Initial modeling studies on 
short antigen fragments show promise: quantum mechanical calculations for 1 RU 
predicted that the 4C1 chair configuration of the mannose ring dominates in both the 
MenA phosphomethyl-monosaccharide and the Carba-MenA analogue.92 More recent 
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molecular dynamics simulations for these 1 RU fragments indicated similar 
conformations, on the basis of which a helical conformation was predicted for both the 
MenA and Carba-MenA polymers.93 However, it is unclear whether a single monomer 
is an appropriate model for the corresponding longer oligosaccharide: these results are 
at variance with our simulations of a long MenA strand (10 RU), which showed the 
saccharide chain to be highly flexible, with no evidence of stable helical 
conformations.1 
Therefore, there remain important conformational questions to be answered for the 
MenA CPS and its Carba-MenA analogue, as follows. Does methylene substitution of 
the mannosamine ring result in a significant difference in the conformation of MenA as 
compared to Carba-MenA? Do MenA and Carba-MenA chains form stable helices in 
solution? What is the optimum chain length for the MenA antigen? 
To shed light on these questions, we extend our previous simulations of MenA (2 RU 
and 10 RU) to the microsecond time scale and compare these to new Carba-MenA 
simulations (2 RU and 10 RU). Comparison of the conformations and dynamic motion 
for the chains highlights the similarities and differences in conformation and flexibility 
of the MenA and Carba-MenA antigens, as discussed below.  
3.4 Results and discussion 
We begin with analysis and comparison of the 10 RU simulations for the MenA and 
Carba-MenA homopolymer chains and then compare these with the corresponding 2 
RU simulations.  
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3.4.1 Oligosaccharide chain conformations 
Our prior study indicated that the MenA CPS behaves as a flexible random coil1 and the 
extension of the original 300 ns simulation to 1 μs corroborates this finding. Here we 
use the end-to-end distance of the 10 RU strand, r1, as a simple measure of 
conformational extension of the 10 RU saccharide (Fig. 3.2a). The time series of r1 
(specifically the distance from C1 of the reducing end to C5 of the non-reducing end of 
the strand) shows rapid transitions between a broad range of values from 9.1 Å to 59.1 
Å (Fig. 3.2b), with a mean of 33.0 Å (standard deviation 8.5 Å). The corresponding 
histogram of r1 (Fig. 3.2c) shows a normal distribution, which indicates random coil 
behavior. However, although flexible on a large scale, the MenA 10 RU chain does 
display some local order, as is revealed by an alternative distance measure, r2, the 
distance from C1 of RU4 to C5 of RU7 (Fig. 3.2a). The MenA time series for r2 (Fig. 
3.2d) also shows considerable flexibility, but alternates between two primary values: a 
population of relatively compact conformations centered on 𝑟𝑟2 ≈ 13 Å (53%), and a 
slightly smaller population of extended conformations centered on 𝑟𝑟2 ≈ 22 Å (47%). 
This bimodal distribution of lengths is clear in the corresponding histogram of r1 (Fig. 
3.2e) and provides evidence of local order in the 4 RU central residues in the MenA 
strand. 
The Carba-MenA 10 RU strands also shows considerable flexibility, as evidenced by the 
broad range of r1 values explored during the simulation (Fig. 3.2f). However, the range 
of values is wider than for MenA (Fig. 3.2g): from 5.6 Å to 59.9 Å, with a mean of 30.4 
Å (standard deviation 10.9 Å). The r2 time series for Carba-MenA (Fig. 3.2h) shows a 
greater difference in the central 4 RU as compared to MenA. In contrast to the bimodal  
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Figure 3.2: Comparison of the end-to-end distance time series for MenA and Carba-
MenA, excluding the first 200 ns of simulation time. (a) We define two end-to-end 
distances: r1 is the distance from C1 of the reducing end to C5 of the non-reducing end 
of the strand; r2 is from RU4 to RU7 and thus excludes the terminal residues. For MenA: 
(b) r1 time series and (c) r1 histogram; (d) r2 time series and I r2 histogram. The 
corresponding graphs for Carba-MenA are shown in (f), (g), (h) and (i) respectively. 
Distances are in Å.  
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MenA, the distribution of r2 for Carba-MenA is more unimodal and centered on 𝑟𝑟 ≈
19 Å.  
The causes of this significant difference in the conformation of the central 4 RU in the 
MenA and Carba-MenA strands are revealed by grouping the conformations into 
families (Fig. 3.3). MenA has two primary conformational families of almost equivalent 
prevalence – Cluster A1 at 32% and Cluster A2 at 27% (Fig. 3.3a). More minor clusters 
(A2, A3 and others) occupy insignificant fractions of the simulation time. Cluster A1 is 
an extended ribbon-like conformation with 𝑟𝑟 ≈ 22 Å and corresponds to the second 
peak in the r2 histogram. In this A1 conformation, the phosphate groups are aligned 
along one edge of the ribbon and the N-acetyl groups aligned along the opposite edge. 
The A1 conformation is stabilized by hydrogen bonds between the O4 hydroxyls and 
the N-acetyls on the adjacent residues. In contrast, Cluster A2 is a compact “S-bend” 
conformation with 𝑟𝑟 ≈ 13 Å, corresponding to the first peak in the r2 histogram. This 
conformation has a tight bend at the glycosidic linkages and is stabilized by hydrogen 
bonds between alternating residues, i.e. between RU4 O4 and the RU6 phosphate as 
well as between RU5 O4 and the RU7 phosphate. 
The primary conformational cluster for the Carba-MenA analogue, cA1 (Fig. 3.3b), is an 
extended conformation similar to A1, with 𝑟𝑟2 ≈ 22 Å. This cluster dominates 
throughout the simulation (41%) and corresponds to the single peak in the r2 
histogram for Carba-MenA. As is the case for the A1 cluster in MenA, the cA1 cluster is 
stabilized by hydrogen bonds between the O4 hydroxyls and the N-acetyls on the 
neighboring linkages, although these hydrogen bonds occur less frequently. A much 
less significant secondary cluster, cA2 (17%), corresponds to a bend in the chain, with  
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Figure 3.3: Conformational families generated by clustering analysis of the central 4 RU 
of the 10 RU strands: (a) MenA and (b) Carba-MenA. The relative percentage 
occupancy of each conformational family is indicated. 
𝑟𝑟 ≈ 15 Å. The compact “S-bend” conformation is absent for Carba-MenA, the range of 
smaller conformational clusters (cA3, cA4 and others) are predominantly extended 
conformations. The Carba-MenA strand thus exhibits a greater range of conformations 
and is generally more extended than MenA, especially on a local (4 RU) scale. These 
differences in conformation between MenA and Carba-MenA are caused by the ring 
methylene group substitution in Carba-MenA changing the dominant orientation of 
the phosphodiester glycosidic linkages, as discussed below. However, this substitution 
does not alter the ring conformations: both MenA and Carba-MenA maintain 4C1 chair 
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conformations of the pyranose rings throughout the simulations, in agreement with 
DFT calculations for the monosaccharide repeat units.92 
3.4.2 Glycosidic linkage conformations 
The orientation of the flexible α(1->6) phosphodiester linkage in MenA is determined 
by the rotation about all the five bonds in the linkage, which is conveniently described 
by five torsion angles: φ, ψ, ω, ε, and χ (labelled on the representative linkages in Fig. 
3.1a MenA and Fig. 3.1b Carba-MenA). These torsion angles vary in their preferred 
orientations and mobility. Our analysis focuses on the center linkage in the 10 RU chain 
(linkage RU5-RU6) as this is representative of the corresponding polymer. For this 
center linkage, the φ and ε torsion angles show little flexibility in both 
oligosaccharides, oscillating around a single conformation: φ = -15°/15° (MenA/Carba-
MenA) and ε = 180° (both). The φ torsion angle is shifted in Carba-MenA, likely due 
repulsion from the hydrogens in the methylene group substituted for O5.  
The remaining torsion angles are more flexible, with frequent conformational 
transitions over the course of the 1 μs simulations. Both the ψ and ω (C-O-P-O) torsion 
angles transition frequently between two main conformations in MenA and Carba-
MenA: 85° and -85°. The χ (primary alcohol) torsion angle has three favored 
orientations: the gg (-60°) and the gt conformations (60°) dominate, with a minor anti 
(180°) population. Carba-MenA shows a lower anti population relative to MenA.  
Experimental corroboration for the torsion angle conformations of the MenA CPS in 
solution is challenging to obtain, as the MenA CPS homopolymer produces NMR NOE 
signals that cannot be unambiguously assigned to either inter- or intramolecular 
correlations. However, the dominant extended conformation we find for the MenA 
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oligosaccharide correlates with reported 3J 31P-13C coupling values that suggest a 
preference for extended anti-conformations of the φ and ε torsion angles.68 In 
addition, an extended conformation is in agreement with a recently reported crystal 
structure of a MenA trimer in complex with a monoclonal antibody, which exhibits a 
linear epitope.94 
A focus on the orientation of individual torsion angles is not appropriate for 
MenA/Carba-MenA, as there are a variety of rotations about the flexible ψ, ω and χ 
torsion angles that will produce similar overall orientations of the linkage; thus, it is 
difficult to draw conclusions based on the analysis of the orientation of individual 
bonds described by torsion angles. However, clustering the orientation of the central 
glycosidic linkage (RU5-RU6) in each chain into conformational families indicates the 
dominant orientation of this linkage throughout the simulations. Such a clustering 
analysis reveals significant differences between the dominant glycosidic linkage 
orientations for MenA and Carba-MenA, as shown in Fig. 3.4. For MenA, there is a 
direct correspondence between the dominant linkage orientations (L1 and L2, Fig. 
3.4a) and the dominant conformations of the central 4 RU (A1 and A2, Fig. 3.3a). The 
central linkage of the MenA strand is split almost equally between extended 
conformations (L1 at 40%) and tight hairpin bend conformations (L2 at 39%). In 
contrast, in Carba-MenA the extended conformations dominate (Fig 3.4b, cL1 at 69%) 
as hairpin bends are very infrequently sampled (cL5 at 6%) and there are intermediate 
conformations that are not significantly populated in MenA (cL2 at 16%, cL3 at 8% and 





Figure 3.4: The dominant conformations of the central linkage in the 10 RU simulations 
of (a) MenA and (b) Carba-MenA, annotated with relative percentage occupancy over 
the 800 ns production run (200 ns equilibration ignored). All atom representations of 
conformations of the central linkage are depicted below for (c) MenA (L1 and L2) and 




In the MenA L2 conformation, a tight hairpin bend conformation of the 
phosphodiester linkage brings the aliphatic hydrogens on C6 into close proximity with 
the ring oxygen on the neighboring sugar residue in MenA, as shown in Fig. 3.4c. For 
the Carba-MenA analogue, O5 is replaced with a methylene group, with consequent 
repulsive forces between the hydrophobic hydrogens in bent conformations (Fig. 3.4d, 
conformation cL5). Therefore, hairpin bends are less common in the Carba-MenA 
analogue. In addition, the relative orientation of the saccharide rings in the dominant 
extended conformation differs in MenA as compared to Carba-MenA: in Carba-MenA 
the saccharide rings are orientated perpendicular to the neighboring sugar as 
compared to the parallel orientation in MenA (compare conformations L1 and cL1 in 
Fig 3.4.). 
Therefore, this significant difference in glycosidic linkage conformations between 
MenA and Carba-MenA can be directly linked to the altered conformational 
preferences of the central 4 RU, as for the 10 RU oligosaccharide chains, as follows. 
Although these are both flexible chains, overall MenA is more conformationally 
defined than Carba-MenA, with oscillations between S-bend and extended 
orientations of the strand. In contrast, Carba-MenA favors extended conformations. It 
is reasonable to expect that the residues in the center of the 10 RU chains will more 
accurately reflect the behaviors of the corresponding polymers, and there may be 
environmental conditions (e.g. increasing ionic strength) that favor more order in the 
polysaccharide chains. Fig. 3.5 illustrates the consequences when the dominant linkage 
conformation is extrapolated to an 18 RU polysaccharide. For MenA, a repeated L1 




Figure 3.5: Extrapolation of the dominant linkage orientations to 18 RU polysaccharide 
conformations in MenA and Carba-MenA. N-acetyl groups are shown in blue and 
phosphate in purple. The ring O5 in MenA is shown in red, whereas the ring methyl in 
Carba-MenA is indicated in black. The L1 conformation when extrapolated to 18 RU 
produces the extended twisted strand shown in (a), whereas the hairpin-bend L2 
conformation produces the short, broad twisted sheet with S-bends shown in (b). The 
18 RU conformation corresponding to cL1 for Carba-MenA, also produces an extended 
conformation (c), but with a different arrangement of the N-acetyl (blue) and 





N-acetyl and phosphate groups arrayed on opposite edges. In contrast, the tight 
hairpin bend L2 orientation of the glycosidic linkage in MenA produces the S-bend 
conformation when repeated in a polysaccharide, which results in a broad, compact 
helix with a dramatically shorter end-to-end distance. As a comparison, Carba-MenA 
not only lacks this chain conformation, but the extended dominant polysaccharide 
structure (Fig. 3.5b) has a different arrangement of N-acetyl and phosphate groups 
than occurs in the extended structure of MenA. 
3.4.3 Chain length effects 
For a vaccine, a short fragment (e.g. 2 RU) of MenA CPS must be representative of the 
full CPS to provide protection against the pathogen. The populations of the φ, ψ, and 
ω torsion angle averages in our 10 RU simulations are largely in agreement with the 
low-energy conformations of phosphomethyl-monosaccharides reported from 
quantum mechanical calculations92 and MD simulations with the GLYCAM06 
forcefield.93 However, the glycosidic linkages in our polysaccharide simulations do not 
explore all of the energy minima previously predicted for the monomers. We therefore 
compare the conformations of the central glycosidic linkage in our 10 RU simulations 
to the conformations of corresponding 2 RU fragments, which reveal both altered 
populations of the primary conformations and additional conformations in the 
disaccharides (Fig. 3.6). For MenA, the large population of extended conformations in 
the 10 RU strand (Fig. 3.6a, L1 40%) is considerably reduced in the disaccharide (Fig. 
3.6c, D2 24%) and the hairpin bend conformations considerably increased (Fig. 3.6c, D1 
49%). The dimer also has conformations that are not significantly populated in the 10 
RU strand (Fig. 3.6c, D3 and D4). The chain length effect is even more pronounced in 
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Carba-MenA (compare Fig. 3.6b and Fig. 3.6d) which shows little correspondence 
between the dominant conformations of the 10 RU strand and the Carba-MenA 
disaccharide. Further, rotations of the ψ, ω, and χ torsion angles occur much more 
frequently in the disaccharides than in the longer chains. These differences suggest 
that, for MenA and Carba-MenA, the disaccharide is not an appropriate model of the 
CPS. This length dependence and the conformational differences between the MenA 
and Carba-MenA linkages provides a rationale for the limited cross-protection 
reported from short Carba-MenA fragments against native MenA CPS.58  
Figure 3.6: Comparison of the dominant conformational families for the central linkage 
in 10 RU simulations (top row, duplicated from Figure 3.4 for ease of comparison) and 
the simulations of the corresponding dimers (bottom row) of MenA (left column) and 




Despite their chemical similarity, our simulations indicate that substitution of the ring 
oxygen for a methylene group causes significant changes in the conformations of 
Carba-MenA as compared to MenA. This is likely due to distinct differences in local 
electron density: the two lone pairs of electrons on the ring oxygen in the MenA RU 
are replaced by two hydrogen atoms on an aliphatic carbon for Carba-MenA, resulting 
in significantly different stereoelectronic constraints on the conformations of the 
adjacent glycosidic linkage. Alterations in the orientations of the flexible α(1->6) 
phosphodiester linkage for Carba-MenA as compared to MenA are manifest as distinct 
differences in the dominant conformations of the central 4 RU, as well as altered 
conformational distributions of the 10 RU strand. Overall, MenA is more 
conformationally defined than Carba-MenA, with oscillations between S-bend and 
extended orientations of the strand. The compact S-bend conformation is absent in 
Carba-MenA, which displays predominantly extended conformations. Further, our 
simulations suggest that the disaccharides are not good models for the corresponding 
10 RU chains. While a single disaccharide can give a good indication of the range of 
possible orientations of a glycosidic linkage, it does not necessarily correctly predict 
their population distribution in the polysaccharide, so care must be taken when 
extrapolating to longer chains. However, although we found neither saccharide to 
form stable helices in solution as predicted by the phosphomethyl-monosaccharide 
simulation, there may be environmental conditions (such as increased ionic strength) 




The torsion angles describing the conformation of the α(1->6) phosphodiester linkage 
of native MenA and Carba-MenA are here defined as: φ = H1-C1-O1-P; ψ = C1-O1-P-
O6’; ω = O1-P-O6’-C6’; ε = P-O6’-C6’-C5’ and χ = O6’-C6’-C5’-O5’ (MenA) or χ = O6’-C6’-
C5’-C7’ (Carba-MenA). 
3.6.1 Molecular dynamics 
We extended our previous simulations of 2 RU and 10 RU of the MenA CPS1 to 1.5 μs 
and 1 μs, respectively and ran the same simulations for Carba-MenA. Simulations were 
performed with version 2.12 of the NAMD molecular dynamics program,33 using CUDA 
extensions for calculation of long-range electrostatic forces and non-bonded forces on 
graphics processing units.69 The glycans were modeled with the CHARMM36 additive 
force field for carbohydrates,31, 32 incorporating ad hoc extensions to represent the 
phosphodiester linkages. Water was simulated with the TIP3P water model,70 which is 
compatible with the CHARMM36 carbohydrate force field. 
The initial structures for all simulations were built using our CarbBuilder software.71, 72 
The starting conformations for the 10 RU simulations were set to the most common 
torsion angle values obtained from the 2 RU simulations. All initial structures were 
subjected to 10,000 steps of standard NAMD minimization in vacuum, followed by 
solvation in a cubic water box using the Visual Molecular Dynamics (VMD) software.73 
The 2 RU simulations used a 40 x 40 x 40 Å cubic cell (2,000 water molecules) and the 
10 RU periodic cubic cells had a side length of 80 Å (16,000 water molecules). Sodium 
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ions were randomly distributed in each simulation using VMD, to neutralize the 
negative charge from each phosphodiester. 
All MD simulations began with a 122,000 step minimization-and-heating phase which 
consisted of 5 K temperature reassignments from an initial 10 K up to a temperature of 
310 K, with 1,000 steps of minimization and 1,000 steps of MD at each temperature.  
The MD equations of motion were integrated with a Leap-Frog Verlet integrator with a 
step size of 1 fs and periodic boundary conditions were employed. Simulations were 
run under the isothermal-isobaric (nPT) ensemble at 310 K, which was sustained by a 
Langevin piston barostat33 and a Nose-Hoover thermostat (a combination of the Nose-
Hoover constant pressure method74 with piston fluctuation control implemented using 
Langevin dynamics75 as implemented in NAMD). Long range electrostatics were 
calculated with particle mesh Ewald (PME)76 summation using k = 0.20 +-1 and PME 
grid dimensions were set to be equal to the periodic cell dimensions of the system. 
Non-bonded interactions were truncated at 15.0 Å with a switching function employed 
between 12.0 and 15.0 Å. The 1-4 interactions were not scaled, in accordance with 
CHARMM force field recommendations. 
3.6.2 Data analysis 
For each simulation, molecular conformations were extracted at 25 ps intervals. The 
first 200 ns of each simulation was discarded as equilibration, to allow for the flexible 
polysaccharides to relax from their initial conformations. This left production runs of 




End-to-end distances were measured as: r1 being the distance from C1 of the reducing 
end to C5, and r2 the distance from C1 of residue 7 to C5 of residue 4. Distances and 
torsion angles were extracted using VMD’s Tcl scripting interface. Statistical values 
were calculated with in-house Python scripts and graphs. Molecular conformations 
extracted from the MD simulations were depicted with VMD, where necessary using 
the PaperChain visualization algorithm for carbohydrates77 to highlight the hexose 
rings.  
Clustering analysis was performed with VMD’s cluster command, which employs the 
quality threshold algorithm.78 For all clustering calculations, the first 200 ns of each 
simulation was excluded. All conformations were first aligned on the ring atoms of a 
single residue: the sixth residue in the 10 RU chain, and the second residue in the 
disaccharide simulation. Clusters were then calculated with a RMSD fit to the non-
hydrogen atoms in the selection (the central 2 RU or 4 RU for the 10 RU strands, the 
entire 2 RU for the disaccharides). The cut-off value for clusters was set to 3.5 Å for all 
2 RU clustering calculations and 5 Å for all 4 RU clustering calculations. Small clusters 
comprising less than 5% of simulation frames were ignored in the analysis. 
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Conformations of S. flexneri serogroup 2: 




The work in this chapter and the next addresses the Shigella flexneri bacterium - the 
dominant pathogen causing diarrheal disease in Africa, particularly in children. Current 
vaccine development is focused on the serotype-defining glycan RUs of the cell-surface 
lipopolysaccharides (LPSs) and these are the polysaccharide chains modeled in this 
work. As no vaccine is currently licensed to prevent disease, initial efforts are 
specifically focused toward developing a vaccine against serogroup 2 – the cause of the 
majority of shigellosis infections globally. 
The following article “The Effects of Glucosylation and O-Acetylation on the 
Conformation of Shigella flexneri Serogroup 2 O-Antigen Vaccine Targets” analyzes the 
effects of O-acetylation and glucosylation on the conformations of the serogroup 2 O-
antigens relative to the unsubstituted backbone (serotype Y). We find important 
conformational differences between serotype 2a and 2b that suggest only partial 
cross-protection will occur. However, the O-acetylated serotype 2a is discovered to 
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have intermediate conformations between 2a and 2b and, therefore, could be 
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Shigellosis is an enteric disease with high morbidity and mortality, particularly in 
developing countries. There is currently no licensed vaccine available. Most infection is 
caused by Shigella flexneri, of which 30 serotypes have been recognized based on O-
antigen polysaccharide structure. Almost all S. flexneri serotypes share the same 
repeating unit backbone (serotype Y), with varying glucosylation, O-acetylation and 
phosphorylation. The O-antigen is the primary vaccine target; the vaccine valency (and 
hence cost) can be reduced by cross-protection. Our planned systematic 
conformational study of S. flexneri starts here with 2a, the dominant cause of infection 
globally.  
We employ microsecond molecular dynamics simulations to compare the 
conformation of the unsubstituted serotype Y backbone with the serogroup 2 O-
antigens, to investigate the effect of glucosylation and O-acetylation (O-factor 9) on 
conformation. We find that serotype Y is highly flexible, whereas glucosylation in 2a 
restricts flexibility and induces C-curve conformations. Further, the glucose side-chains 
adopt two distinct conformations, corroborated by the antibody-bound crystal 
structure data. Additional substitution on O-3 of rhamnose A (whether O-acetylation in 
2a or glucosylation in 2b) induces helical conformations. Our results suggest that the 
O-3-acetylated 2a antigen will elicit cross-protection against 2b, as well as other 




Shigella is one of the five most prevalent diarrheal bacterial pathogens globally, with 
an annual rate of several hundred million cases of shigellosis infection and up to 
800,000 deaths, mainly in sub-Saharan Africa and Asia.95-97 Due to the extent of this 
global disease burden, combined with rising antibiotic resistance, Shigella is a major 
worldwide health concern and there is a pressing need for the development of a broad 
coverage Shigella vaccine.98 
Shigella flexneri accounts for approximately 60% of all shigellosis cases. S. flexneri is 
categorized into 7 serogroups and approximately 30 serotypes, which are 
characterized by the O-antigen (O-Ag) repeating unit structure expressed on the cell-
surface lipopolysaccharide.99, 100 The O-Ag surface glycans are important vaccination 
targets.101 With the exception of serotype 6, all S. flexneri O-Ags share the same 
tetrasaccharide backbone repeating unit (RU), serotype Y:→2)-α-L-RhapIII-(1→2)-α-L-
RhapII-(1→3)-α-L-RhapI-(1→3)-β-D-GlcpNAc-(1→ (Fig. 4.1a). The serotypes differ, with 
varying glucosylation, O-acetylation and phosphorylation giving rise to the serotypes 
observed.99, 102, 103 For Shigella, the common backbone and shared substitution 
patterns raise the possibility of developing a vaccine with broad coverage, which 
would reduce vaccine complexity and costs.98, 104-106 The Global Enteric Multicenter 
Study (GEMS) suggested that a quadrivalent vaccine — containing S. flexneri serotypes 
2a, 3a and 6 as well as the sole serotype of S. sonnei— could provide direct protection 
against 64% of Shigella strains causing infection in children in low-income areas, with 
cross-reactivity potentially extending this to 88% overall coverage.95, 107 
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Figure 4.1: Line structures and schematic diagrams of the O-Ag repeating units of 
Shigella flexneri (a) serotype Y, (b) serotype 2a, and (c) serotype 2b. Serogroup 2 all 
have the same tetrasaccharide backbone repeating unit as serotype Y, with 
glucosylation on O-4 of rhamnose C. Serotype 2a has non-stoichiometric O-acetylation 
in two positions and serotype 2b has glucosylation on rhamnose A. Diagrams are 
depicted using the ESN symbol set108 with: green triangle - Rha, blue square - GlcNAc, 
blue circle - Glc. 
We focus here on serotype 2a, which causes the majority of S. flexneri infection and is 
thus the primary target of current vaccine development efforts.109, 110 The 2a O-Ag 
adds glucosylation on O-4 of rhamnose C to the common backbone (serotype Y, Fig. 
4.1a). The 2a native polysaccharide (Fig. 4.1b) includes partial O-acetylation at O-3 of 
rhamnose A (O-factor 9, ~65%), O-4 of rhamnose A (~25%) and O-6 of GlcNAc (O-factor 
10, ~60%). However, the level and position of O-acetylation reported can be affected 
by the strain, method of isolation/purification and storage conditions for the O-Ag.99 
Serotype 2b has additional glucosylation at O-3 of rhamnose A and no O-acetylation 
(Fig. 4.1c).  
Similarity in antigen primary structure does not necessarily result in strong cross-
reactivity between closely related antigens, as small differences in glycan structure can 
81 
 
significantly alter chain conformation and molecular flexibility. Therefore, 
conformational analysis can play an important role in investigating cross-reactivity 
between antigens.22 
For serogroup 2, studies in the 1990s showed limited cross-protection conferred by 2a 
against both serotype 2b and serotype Y.104, 106 However, the immunogens were not 
yet fully characterized and the 2a O-acetylation pattern was only determined in 
2007.111 Recent clinical trials with non-acetylated 2a conjugate vaccines have raised 
functional antibodies against 2a, but cross-protection against other serotypes has not 
been reported.110, 112 
In general, O-acetylation has been identified as an important epitope in S. flexneri 2a 
cross-reactivity and is in need of further investigation.113 In particular, O-3 acetylation 
(designated O-factor 9)99 significantly affects binding of monoclonal antibodies, 
suggesting the importance of this epitope for antigenicity, while O-6 acetylation on 
GlcNAc (O-factor 10)99 has only a minor effect on antibody binding.114 Indeed, O-factor 
9 is the likely reason for antibody cross-reactivity observed against serotype 6 
following 2a conjugate vaccination in humans.115 O-factor 9 is also present on Shigella 
serotypes 1a1, 1b, 5a1, Y1 and 7a1,99, 116 which may offer broader S. flexneri coverage. 
Molecular dynamics (MD) is increasingly used to investigate glycan antigen 
conformations in order to compare related serotypes and rationalize cross-protection 
phenomena.1, 117-121 Previous MD simulations of 4 RU of the Shigella serotype Y 
polysaccharide indicate a flexible backbone with a diverse array of conformations.122 
Short simulations (60 – 350 ns) of twelve S. flexneri O-Ags showed very similar 
backbone linkage conformations for 3 RU strands across the different serotypes: the 
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effect of substituents was to limit the conformations that the backbone could adopt.123 
However, chain length may be a factor, as differing conformations for varying chain 
lengths have been observed in MD simulations of glycan antigens1, 2 and, for flexible 
glycans, simulations of over 1 μs may be necessary to replicate native polysaccharide 
behavior.120 
There remain important conformational questions for the S. flexneri serogroup 2 O-
Ags, as follows. Does serotype 2a (glucosylation on rhamnose C) have altered 
conformation and flexibility relative to the serotype Y (unbranched backbone)? Does 
O-3 acetylation on rhamnose A (O-factor 9) alter the conformation of a non-acetylated 
serotype 2a? Does serotype 2b (with additional glucosylation on rhamnose A) have a 
different conformation to serotype 2a? 
To investigate these questions, we compare microsecond MD simulations of 6 RU 
polysaccharides of the serogroup 2 O-Ags (comprising serotype 2a, 2a with O-3 
acetylation on rhamnose A, and 2b) with the unsubstituted backbone O-Ag (serotype 
Y). The conformations of 2a and Y are corroborated by comparison with published X-
ray crystal structures of monoclonal antibodies bound to O-Ag fragments. Comparison 
of the polysaccharide conformations from these simulations is discussed in light of 
potential cross-reactivity to inform future vaccine design. This work is the first stage of 
our planned systematic study of the conformations of key Shigella flexneri O-Ags. 
4.4 Materials and methods 
The glycosidic linkages in the S. flexneri polysaccharides are described by two torsion 
angles defined as: φ = H1-C1-O1-Cx’ and ψ = C1-O1-Cx’-Hx’. These torsion angles are 
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analogous to φH and ψH in IUPAC convention and are consistent with our previous 
modeling studies.2, 27, 124 Our established systematic approach to modeling of 
polysaccharide antigens involves first determining the preferred conformations of each 
glycosidic linkage in the polysaccharide by calculation of the φ, ψ potential of mean 
force (PMF) for the corresponding disaccharide linkages and then progress to 
molecular dynamics simulations of oligosaccharides in aqueous solution to establish 
the preferred conformations and dynamics of the glycan chains.1, 65, 120 
4.4.1 Disaccharide PMF calculations 
We identified the preferred conformations of the each of the glycosidic linkages by 
calculation of the potential of mean force (PMF) for rotation about the φ and ψ torsion 
angles. PMFs were calculated using the metadynamics36 routine incorporated into 
NAMD33, with the glycosidic linkage torsion angles used as collective variables. All PMF 
surfaces were calculated in the gas-phase. 
4.4.2 Molecular dynamics 
All simulations were performed using the NAMD software package33 with CUDA 
extensions for accelerated calculation of long-range electrostatic potentials and non-
bonded forces on graphics processing units.69 All structures were built with our in-
house CarbBuilder software71, 72 and modeled with the CHARMM36 additive force field 
for carbohydrates.31, 32 The TIP3P model70 was used to simulate water. 
Initial chains of 3 RU of the S. flexneri O-Ags (not discussed here) were built with 
torsion angles set to the respective energy minima calculated in the PMFs. The 3 RU 
simulations were run in solution for 300 ns and the most common torsion angles from 
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these simulations were used to build the longer 6 RU polysaccharides reported in this 
study. All starting structures underwent 10,000 steps of standard NAMD minimization 
in vacuum and were then solvated in a cubic water box with the solvate command in 
the Visual Molecular Dynamics (VMD) program.73 The 6 RU structures were placed into 
a cubic water box with side lengths of 90 Å (~23,000 water molecules). Periodic 
boundary conditions were employed for the solvated simulations. All solvated MD 
simulations first underwent a minimization-and-heating protocol of 122,000 steps, 
consisting of 5 K incremental temperature reassignments beginning at 10 K up to 310 
K, with 1,000 steps of NAMD minimization and 1,000 steps of MD at each temperature 
reassignment. 
A Leap-Frog Verlet integrator was used to integrate the MD equations of motion using 
a step size of 1 fs. Simulations were sampled under the isothermal-isobaric (nPT) 
ensemble at 310 K, which was achieved with the use of a Langevin piston barostat33 
and a Nose-Hoover thermostat (a hybrid of the Nose-Hoover constant pressure 
method125 with piston fluctuation controlled using Langevin dynamics75 as 
implemented in NAMD. Long-range electrostatics were implemented with particle 
mesh Ewald (PME) summation76 with k = 0.20 Å-1 and PME grid dimensions that were 
set to 90 Å for the 6 RU simulations. Non-bonded forces were truncated at 15.0 Å with 
a switching function applied from 12.0 Å to 15.0 Å. The 1-4 interactions were not 
scaled, in accordance with CHARMM force field recommendations. 
4.4.3 Data analysis 
Molecular conformations were sampled at 12.5 ps intervals. The simulations 
equilibrated for 200 ns, after which production runs of 800 ns were performed. Inter-
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atomic distances and torsion angles were extracted using VMD’s Tcl scripting and 
graphical user interfaces. The end-to-end distance, r, was measured between C2 of 
rhamnose B at the non-reducing end and C1 of rhamnose C at the reducing end, 
excluding the more flexible terminal residues which are less representative of the 
native O-Ag polymer. Statistical measures were calculated with in-house Python 
scripts. For the antibody-bound serotype 2a conformations, the median torsion angle 
of the four decasaccharides was plotted on the respective φ/ψ plots. Heat maps were 
generated from measurements of the φ/ψ torsion angles from the glycosidic linkages 
of both central repeating units, where the torsion angles from each frame were sorted 
into bins with a size of 1 degree in each dimension.  
VMD73 was used to visualize the extracted molecular conformations, making use of the 
PaperChain visualization algorithm77 to highlight the carbohydrate rings. 
Conformational clusters were calculated from the 800 ns production runs with VMD’s 
internal cluster command. Before clustering, the time series trajectory snapshots were 
first aligned on the ring atoms of the ‘B-C’ disaccharide fragment of RU3 – a central 
fragment with the least linkage flexibility. Clusters were then calculated with a RMSD 
fit to the non-hydrogen atoms of the central 4 RUs with the cut-off criterion set to 6.5 
Å.  
4.5 Results 
We begin with a broad comparison of the chain extension and flexibility of the S. 
flexneri backbone (serotype Y) with the serogroup 2 O-Ags. We then explore the 
effects of glucose side-chains and rhamnose O-acetylation on the backbone 
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conformation. Finally, we link the differences in serogroup 2 conformations to altered 
orientations of specific backbone glycosidic linkages.  
To investigate the issue of convergence in the simulations, we performed block 
averaging analysis35, 126 of the end-to-end distance, r, and the radius of gyration, Rg, for 
the 6 RU chains (Supp. Fig. S4.1a and S4.1b). Overall, the blocked standard errors reach 
a plateau for both measures in each O-Ag simulation, indicating convergence.50 
Correlation times of less than 45 ns for all serotypes indicate that 200 ns is a sufficient 
equilibration time and also that the 6 RU O-Ags are adequately sampled over the 
course of the 800 ns production runs. 
4.5.1 O-Ag chain extension and flexibility 
The end-to-end distance, r, is a measure of glycan chain extension and the r time series 
(a plot of r versus time) is a simple visualization of molecular flexibility. We define r for 
all O-Ags as the distance between C2 of rhamnose B in RU1 and C1 of rhamnose C in 
RU6 for the glycan backbone (Fig. 4.2a).  
The r time series for serotype Y O-Ag (Fig. 4.2b) demonstrates the extreme flexibility of 
the unbranched backbone, which rapidly transitions through a broad range of values 
from 7 Å to 74 Å. The corresponding r histogram (Fig. 4.2c) has two peaks: a population 
of extended conformations (peak at r = 54 Å) comprising 59% of the 800 ns simulation 
and a population of compact conformations (peak at r = 24 Å) comprising 41% of the 
simulation. 
In contrast, the r time series for the 2a O-Ag (Fig. 4.2d) has a more restricted range (5 Å 




Figure 4.2: Comparison of the r time series and distribution for 6 RU of serotype Y 
and serogroup 2 O-antigens, excluding the first 200 ns of each simulation. (a) A 
model of the 6 RU Y chain with the end-to-end distance, r, indicated; rhamnose is 
colored pink and N-acetyl-glucosamine blue. The line graphs show the r time series 
(left column) and the bar graphs the corresponding histograms (right column) for Y 
(grey, b and c); 2a (orange, d and e); 2a with O-3 acetylation (red, f and g); and 2b 




corresponding histogram for serotype 2a (Fig. 4.2e) shows a unimodal, right-skewed 
distribution with a peak at r ≈ 14 Å (mean 20 Å, σ = 9 Å). This difference between the Y 
backbone and the branched 2a O-Ag indicates that glucosylation of the backbone has a 
conformational effect, resulting in a predominance of compact, curved conformations 
of the backbone in 2a.  
The 2a-3Ac O-Ag has similar flexibility to 2a, with values of r ranging from 6 Å to 55 Å 
(Fig. 4.2f), but O-acetylation at position 3 of rhamnose A (O-factor 9) shifts r to a 
symmetrical unimodal distribution with a peak at r ≈ 26 Å, σ = 8 Å (Fig. 4.2g). Thus, O-
factor 9 has direct conformational consequences, resulting in more extended 
conformations for the O-acetylated 2a O-Ag. 
The 2b O-Ag is similarly flexible, with r ranging from 13 Å to 60 Å (Fig. 4.2h). The 
additional glucosylation at position 3 of rhamnose A also shifts the values of r relative 
to the 2a chain: the r distribution has a peak at r ≈ 33 Å, σ = 8 Å (Fig. 4.2i). Thus, 
glucosylation at O3 has an equivalent effect on chain extension to O-3 acetylation: 
compare the similar profiles for the corresponding histograms Fig. 4.2g and 4.2i. The 
reasons for these fairly dramatic shifts in chain extension are revealed in a detailed 
examination of the chain conformations for the O-Ags, as discussed below. 
4.5.2 O-Ag chain conformations 
The dominant conformational families and associated frequencies for each O-Ag chain 
are shown in Fig. 4.3. Here we consider only the conformation of the middle 4 RU of 
each O-Ag, as the ends of the 6 RU chain are less representative of the conformation of 
a S. flexneri O-Ag polysaccharide. 
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The extreme flexibility of the serotype Y antigen (unbranched backbone) is 
demonstrated by the high number of conformational families observed for this O-Ag 
(Fig. 4.3a). The two peaks in the r histogram for the Y O-Ag (Fig. 4.2c) are not 
associated with specific conformations, but rather reflect a range of both compact and 
extended conformations. As expected from the r histogram, the predominant cluster 
(Y1) is an extended conformation (r = 54 Å). This is in agreement with an early 
conformational prediction by the HSEA method.127 However, cluster Y1 encompasses 
just 25% of the simulation conformations, with a smaller distinct extended family (Y3, 
with a tight bend in the middle of the chain) representing a further 12% of the 
simulation’s conformations. Similarly, there are a range of compact conformations (Y2, 
Y4) that contribute to the peak at r = 24 Å in the histogram. This diverse range of 
conformations, together with their low occupancies, indicates that the Y O-Ag is a 
highly flexible polysaccharide. Our results are in good agreement with a previous MD 
study of serotype Y, also finding a wide array of conformations in shorter chains of up 
to four repeating units.122 
For the 2a O-Ag, the r time series indicates a flexible molecule, but with a shift to more 
compact conformations relative to the Y backbone. Indeed, the dominant 
conformation (Fig. 4.3b, cluster 2a-1) is a compact C-curve with ends in close 
proximity, representing 38% of the simulation. The second conformational cluster is a 
similar, but slightly distorted, curve (2a-2, 17%). The final small cluster (2a-3) is a 
helical conformation, but occupies only 13% of simulation time. There are no 
significant families of extended conformations for 2a, as expected from the skewed 




Figure 4.3: Conformational families of the central 4 RU of the 6 RU chains: (a) Y, (b) 
2a, (c) rhamnose A O-3 acetylated 2a and (d) 2b. The relative percentage occupancy 
of each conformational family during the 800 ns production run (ignoring the initial 
200 ns) is indicated; clusters below 7% are not shown. The sugars are colored as 
indicated in the legend: pink for Rha, dark-blue for GlcNAc, cyan for Glc side chains, 





Conformational analysis reveals that O-3-acetylation on rhamnose A (O-factor 9) in the 
2a O-Ag causes a significant conformational change in the 2a backbone from a flexible 
C-curve to a more stable helix (Fig. 4.3c), resulting in the more extended 
conformations seen in the r histogram (Fig. 4.2g). The helix of the primary 
conformational cluster has 3 RU per turn and a helical pitch of 18 Å, comprising 50% of 
the simulation time (Fig. 4.3c, 2a3Ac-1). A secondary cluster occupies 15% of the 
simulation time and represents a more extended helix, also with 3 RU per turn but 
with a pitch of 28 Å (Fig. 4.3c, 2a3Ac-2). A curved conformation similar to the de-O-
acetylated 2a O-Ag occurs for only 11% of the simulation (Fig. 4.3c, 2a3Ac-3). The O-
acetyl groups are also exposed on the outside edge of the helices, and so would be 
accessible for antibody binding. 
Glucosylation at position 3 of rhamnose A has equivalent conformational 
consequences to O-3-acetylation, favoring more stable helical conformations over 
looser curved conformations (Fig. 4.3d). Indeed, comparison of the two primary 
conformational clusters of the 2b O-Ag (Fig. 4.3d) with the 2a-3Ac O-Ag (Fig. 4.3c) 
shows similar helical conformations and populations over the 800 ns simulation. The 
chief 2b conformational cluster, 2b-1, is comparable to 2a3Ac-1: a 3 RU-per-turn helix 
with a pitch of 18 Å. The minor clusters are representative of extensions (cluster 2b-2) 
and compressions (2b-3) of this helix. Therefore, these simulations show that 
substitution at position 3 of rhamnose A, be it O-acetylation or glucosylation, results in 
a helical conformation of the serogroup 2 O-Ags. 
92 
 
4.5.3 O-Ag glycosidic linkage conformations 
Conformational changes in an O-Ag chain are brought about primarily from changes in 
the orientations of the constituent glycosidic linkages, because the ring conformations 
of the monosaccharides are typically relatively constrained. The range of motion and 
the dominant orientations of each glycosidic linkage in the central RU of each O-Ag 
strand over the course of the simulations is depicted with heat maps of the linkage 
torsion angles, φ and ψ, shown in Fig. 4.4. 
All the backbone glycosidic linkages – in the Y, 2a and 2b O-Ags – show a narrow range 
of φ torsion values centered on φ ≈ 40° and more flexibility in the ψ torsion angles, 
with two primary ψ conformations at ψ ≈ 14° and ψ ≈ -35° (from here on referred to as 
+ψ and -ψ). Broadly, the torsion angle populations for the unbranched Y O-Ag (Fig. 
4.4a) are consistent with previous MD simulations122 as well as with the published X-
ray crystal structure of a monoclonal antibody bound to a Y pentasaccharide.128 
Further, for the non-acetylated 2a and serotype 2b, our linkage analysis is in good 
agreement with previous simulations of 3 RU chains.123 
The α-L-RhapII-(1→3)-α-L-RhapI (B-C) linkage is the most constrained of the backbone 
linkages and is relatively consistent across the serogroup 2 O-Ags (Fig. 4.4, second 
column). This linkage is moderately affected by steric interactions with the 
glucosylation at O-4 on residue C, shifting from φ, ψ ≈ 40°, 8°(+ψ) in unbranched Y to 
φ, ψ ≈ 40°, -22°(-ψ) in the glucosylated serogroup 2 O-Ags. The neighboring α-L-RhapIII-
(1→2)-α-L-RhapII (A-B) linkage is more dramatically affected by glucosylation at 
rhamnose C: this linkage favors φ, ψ≈48°, 17° (+ψ) in Y, which shifts to φ, ψ ≈39°, -39° 




Figure 4.4: Scatter plots illustrated as heat maps, with heat scale on the right, for the 
torsion angles (φ, ψ) of each glycosidic linkage in the repeating unit: (a) Y, (b) 2a, (c) 
rhamnose A O-3 acetylated 2a, and (d) 2b. The white cross symbols on the plots of Y 
and 2a correspond to the torsion angles adopted in the bound states to respective 
serospecific antibodies in published crystal structures.128, 129 The E-C linkage of the 
serogroup 2 O-Ag can adopt two distinct conformations (as indicated for 2a, fifth 
column). These correspond to a perpendicular (white square) and a face-on (white 
triangle) orientation. 
and B-C linkages to -ψ conformations in the branched O-Ag causes significant 
curvature in the saccharide chain: a Y backbone with all +ψ linkages is an extended 
chain (Supp. Fig. S4.2a), whereas all -ψ rotations result in a curved conformation 
(Supp. Fig. S4.2b). Overall, this shift in glycosidic linkage orientation results in the 
curved conformations that dominate for glucosylated 2a and 2b O-Ags. 
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The α-L-RhapI-(1→3)-β-D-GlcpNAc linkage (C-D, third column in Fig. 4.4) is the most 
flexible linkage and its conformation is similar across all O-Ags, with ψ ranging from 
+30° to -60°. This linkage is therefore the primary source of conformational flexibility, 
particularly in the branched O-Ags.  
The β-D-GlcpNAc-(1→2)-α-L-RhapIII (D-A, Fig. 4.4, fourth column) linkage shows the 
greatest difference between the Y, 2a, 2a-3Ac and 2b O-Ags, which is unsurprising as 
the adjacent α-L-RhapI (A) residue has various substitutions across the four O-Ags. 
Alterations in the conformation of this linkage are therefore the source of most of the 
conformational variation between the serogroup 2 O-Ags. The D-A linkage in Y (Fig. 
4.4a, fourth column) and 2a (Fig. 4.4b, fourth column) have a similar distribution, with 
two primary conformations (+ψ and -ψ), indicating a flexible linkage. However, both O-
3-acetylation on rhamnose A (2a-3Ac, Fig. 4.4c, fourth column) and 3-glucosylation at 
rhamnose A (2b, Fig. 4.4d, fourth column) narrow the range of this linkage to a single 
dominant conformation, with ψ ≈ -20° (2a-3Ac) and ψ ≈ -1° (2b). This is due to 
interactions between the substituent (O-Ac or glucose) and the N-acetyl group on D, 
which restricts rotation of the D-A linkage. This additional constraint on the backbone 
orientation produces the dominant helical conformational families seen for the 2a-3Ac 
and 2b O-Ags (Supp. Fig. S4.2c). However, rotations in the C-D linkages still allow the 
helical conformations significant flexibility. 
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The heatmaps for the α-D-Glcp-(1→ 3)-α-L-RhapI linkage (E-C, Fig. 4.4, fifth column) are 
rather unusual, with two disjoint populations: a primary population at φ, ψ = -17°, 59° 
(+ψ, 74%) and a secondary population at φ, ψ = -53°, -30° (-ψ, 26%). This is consistent 
across the 2a, 2a-3Ac and 2b O-Ags. Torsion angles for this linkage in a crystal structure 
of a monoclonal antibody bound to four decasaccharide (2 RU) chains of de-O-
acetylated 2a129 are in agreement with the simulation populations (Fig. 4.4b – white 
crosses on heatmaps). Interestingly, the two α-glucose side chains in the 
decasaccharide (Fig. 4.4e) are each bound to the antibody with a different 
conformation, corresponding to the two dominant conformations from our MD 
simulations, illustrated in Fig. 4.5a and 4.5b, respectively. The +ψ state orientation is 
Figure 4.5: The two conformations of the glucose side chain (residue E) on rhamnose 
C of the serogroup 2 O-antigens: (a) perpendicular orientation (+ψ; white square on 
bound crystal structure - Fig. 4.4e) and (b) face-on orientation (-ψ, white triangle on 
bound crystal structure – Fig. 4.4e). The dominant perpendicular orientation is 
stabilized by a hydrogen bond between the O6 hydroxyl of glucose E and the ring 




partially stabilized by a hydrogen bond between the O-6 hydroxyl of α-glucose (residue 
E) to the ring oxygen of rhamnose A (Fig. 4.5b). Previous MD simulations of serotype 2 
also found two populations for this linkage, albeit with altered occupancies.123 The 
disjoint populations for this linkage are a result of high-energy steric clashes in the 
intermediate conformations, between the primary hydroxyl of the glucose side chain 
and the backbone. This is evidenced by a comparison of calculated φ, ψ PMFs for this 
linkage in the α-D-Glcp-(1→ 3)-α-L-Rhap disaccharide (Supp. Fig. S4.3a) and a 
pentasaccharide RU of 2a (Supp. Fig. S4.3b): the pentasaccharide PMF shows two low-
energy conformations (the +ψ orientation is 1 kcal.mol-1 lower in energy) separated by 
a 3-4 kcal.mol-1 energy barrier. 
4.6 Discussion and conclusions 
For this computational investigation into the effects of glucosylation and O-acetylation 
on the conformations of S. flexneri serogroup 2 O-antigens, we use the unbranched 
serotype Y O-Ag as a reference for comparison. We find that our extended simulation 
of a longer repeating unit of the serotype Y O-Ag agrees with the diverse array of 
conformations reported in previous MD simulations122, as well as with the published X-
ray crystal structure of a monoclonal antibody bound to a Y pentasaccharide.128 
Although the unbranched serotype Y O-Ag is very flexible, the glucosylation that 
defines serogroup 2 (O-4 of rhamnose C) restricts the range of motion of the 2a O-Ag, 
resulting in flexible C-curve conformations as compared to the more extended chains 
that predominate in serotype Y. However, the prevalence of C-curve conformations in 
both 2a and the Y backbone may provide a rationale for the partial cross-reactivity 
elicited from 2a anti-sera against the Y O-Ag in early immunological studies.104 
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Our simulations show two dominant orientations for the glucose branch on O-4 of 
rhamnose C (serogroup 2), which we attribute to steric clashes between the primary 
hydroxyl of the glucose side chain and the backbone. The existence of two orientations 
for this side chain is corroborated by the presence of the same two orientations in the 
glucose side chains of a 2 RU antibody-bound X-ray crystal structure.129  
O-3-acetylation of rhamnose A (O-factor 9) in serogroup 2 limits the flexibility of the O-
Ag backbone, changing the dominant conformation from a C-curve to a helix with 
solvent exposed epitopes. This change provides a rationale for the strong influence of 
O-factor 9 in antibody binding to a range of synthetic 2a oligosaccharides.114 Further, 
this may provide insight into the cross-reactivity observed between antibody raised by 
an O-acetylated 2a vaccine and serotype 6, which shares the O-factor 9 epitope.115 O-
factor 9 is also present on Shigella serotypes 1a1, 1b, 5a1, Y1, and 7a199, 116, providing 
the possibility of cross-protection with O-3-acetylated 2a. 
Glucosylation on O-3 of rhamnose A also restricts the O-Ag flexibility, producing quite 
well-defined helices for serotype 2b as well. Therefore, we find that substitution at 
position 3 of rhamnose A, be it O-acetylation or glucosylation, results in a similar 
helical conformational of the serogroup 2 O-Ag. Overall, this similarity in conformation 
suggests that the 2a O-Ag with O-factor 9 could be a better antigen for eliciting cross-
reacting antibodies against 2b, compared to 2a without O-acetylation. We hope that 
ongoing pre-clinical or clinical studies on Shigella vaccines currently under 
development will support our findings. 
Future investigation is needed into the effect, if any, of acetylation on O-6 of GlcNAc 
(O-factor 10). These results, showing a significant effect of O-acetyl and glucose 
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substitution patterns on Shigella O-Ag conformations, can inform the rational selection 
of suitable vaccine antigens to achieve the broadest possible cross-protection against 
shigellosis. 
4.7 Associated content 
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Supplementary Figure S4.1: Block averaging analysis calculated for the time series 
of end to end distance (a) and radius of gyration (b) of the 6 RU O-Ags. The blocked 
standard error (BSE) reaches a plateau for all the O-Ags, indicating convergence of 
the simulation. Further analysis reveals correlation times consistently less than 45 






Supplementary Figure S4.2: The 6 RU static models of the serotype Y backbone built 
by extrapolation of the dominant linkage conformations in the simulations which 
demonstrate the extremes in the polysaccharide motion. (a) A model with all 
linkages in the +ψ orientation. This creates an extended conformation and 
corresponds to the extended conformations (cluster Y1) only observed for Y. (b) The 
6 RU model with linkages in the -ψ orientation produces a rounded conformation 
which corresponds to the conformations of 2a-3Ac. (c) The helical model produced 
by -ψ orientations in the A-B and B-C linkages with +ψ orientations in the C-D and 










Supplementary Figure S4.3: Vacuum PMF plots of the α-D-glucose-(1->4)-α-L-
rhamnose linkage corresponding to the E-C linkages of 2a for: (a) the Glcp-(1→ 4)-α-
L-Rhap disaccharide and (b) a full pentasaccharide 2a repeating unit. The presence 
of the adjacent rhamnose (residue B) sterically constrains the E-C linkage to two 





Cross-protection from a S. flexneri 




The following article “Molecular Modeling of the Shigella flexneri Serogroup 3 and 5 O-
Antigens and Conformational Relationships for a Vaccine Containing Serotypes 2a and 
3a” expands the investigation of S. flexneri O-Ags to determine the prospect of cross-
protection occurring from a proposed multivalent vaccine that includes serotypes 2a 
and 3a.  
As the chemical structure of the S. flexneri O-Ags are fairly conserved between strains, 
a multivalent vaccine with just three strains of S. flexneri (serotypes 2a, 3a and 6) is 
proposed to provide protection against the majority of prevalent infectious strains. 
Together, serotypes 2a and 3a express shared antigenic epitopes with almost all 
remaining serotypes, except for serotype 6. As vaccine development is still ongoing, 
only limited cross-reactivity data is available. Therefore, molecular dynamics 
simulations can offer valuable insights to guide the investigation toward an optimal set 
of vaccine components for a multivalent Shigella vaccine. 
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In addition to the serogroup 2 O-Ags studied in the previous chapter, this study 
considers serogroup 3 as well as the non-vaccine serogroup 5. We identify three 
general heuristics for the conformational effects of different substitution patterns on 
the →2)-α-L-RhapIII-(1→2)-α-L-RhapII-(1→3)-α-L-RhapI-(1→3)-β-D-GlcpNAc-(1→ O-Ag 
backbone (residues ‘A-B-C-D’): first, substitution on rhamnose C reduces overall chain 
extension; second, substitution on rhamnose A induces predominantly helical 
conformations; third, substitution on rhamnose B has only a minor conformational 
effect. Further, our modeling indicates that broad cross-protection against non-vaccine 
strains is likely from vaccination with serotypes 2a and 3a, through shared C-curve and 
helical conformations. These results support and guide the development of an 
envisioned broad-coverage multivalent Shigella vaccine.  
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The pathogenic bacterium Shigella flexneri is a leading global cause of diarrheal 
disease. The O-antigen is the primary vaccine target and distinguishes the 30 serotypes 
reported. Except for serotype 6, all S. flexneri serotypes have a common backbone 
repeating unit (serotype Y), with variations in substitution creating the various 
serotypes. A quadrivalent vaccine containing serotypes 2a and 3a (as well as 6 and S. 
sonnei) is proposed to provide broad protection against non-vaccine S. flexneri 
serotypes through shared epitopes and conformations. 
Here we model the O-antigen conformations of serogroups 3 and 5: a continuation of 
our ongoing systematic study S. flexneri O-antigens that began with serogroup 2. Our 
simulations show that S. flexneri serogroups 2, 3 and 5 all have flexible O-Ags, with 
substitutions of the backbone altering the chain conformations in different ways. Our 
analysis suggests three general heuristics for the effects of substitution on the Shigella 
O-Ag conformations: (1) substitution on rhamnose C reduces the extension of the O-Ag 
chain; (2) substitution at O-3 of rhamnose A restricts the O-Ag’s to predominantly 
helical conformations, (3) substitution at O-3 of rhamnose B has only a slight effect on 
conformation. The common O-Ag conformations across serotypes identified in this 
work support the assumption that a quadrivalent vaccine containing serotypes 2a and 




Diarrheal diseases cause over 1.6 million deaths each year,96 disproportionately 
affecting low-income regions130 and young children.95 Shigella flexneri is a leading 
cause of enteric infections, with no licensed vaccine currently available.131 The 
increasing prevalence of antibiotic resistant strains132-135 necessitates a broad coverage 
Shigella vaccine to prevent infection131, 136 and reduce the global disease burden.137, 138 
The structure of the S. flexneri O-antigen (O-Ag) repeating unit (RU) - the glycan 
component of the cell-surface lipopolysaccharide - classifies strains into approximately 
30 serotypes and 7 serogroups.100, 139 The O-Ag is the primary target of the host 
immune response140, 141 and is a focus of current vaccine development.101, 113 Except 
for serotype 6, all S. flexneri serotypes have the same backbone RU - serotype Y: →2)-
α-L-RhapIII-(1→2)-α-L-RhapII-(1→3)-α-L-RhapI-(1→3)-β-D-GlcpNAc-(1→ (Figure 5.1a). 
Serotypes are defined by the combination of type O-factor epitopes in the O-Ag RU 
(which distinguish the serogroups from each other) as well as the group O-factors 
determined by glucosylation, O-acetylation and phosphorylation substitution of the 
serotype Y backbone, which appear across serogroups.139, 142 The similarities between 
S. flexneri O-Ags (shared backbone and group O-factors) suggest that some serotypes 
may cross-protect, enabling development of a broad-coverage vaccine with minimal 
valency. The proposed vaccine for Shigella based on the Global Enteric Multicenter 
Study (GEMS) consists of S. flexneri serotypes 2a, 3a, 6 and the single S. sonnei 
serotype, which is estimated to provide direct protection against 64% of Shigella 
strains causing infection in children in low-income areas, with cross-reactivity 
potentially extending this up to 88%.98, 105, 107 Serotypes 2a and 3a were chosen as 
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vaccine components because both are prevalent causes of infection (ranked 1st and 4th, 
respectively) and together they express the group O-factor epitopes (group O-factor 6, 
7,8 and 9) found on most remaining non-vaccine serotypes, allowing for potential 
broad cross-protection.  
As cross-protection between antigens is expected to require both chemical and 
conformational similarity,22 molecular modeling can provide insight into the potential 
for cross-protection between S. flexneri O-Ags. Early computational models indicated 
an extended conformation for serotype Y,143 and a helix for serotype 5a.127 However, 
MD simulations predicted a that serotype Y is highly flexible 144, 145 and that 3 RU of 12 
S. flexneri O-Ags show similar conformations to each other.146,147. Although S. flexneri 
expresses a heterogenous distribution of O-Ag chain lengths, 3 RU is considered 
sufficient to represent the O-antigen conformation.113, 146 
We previously embarked on a systematic conformational study of all the Shigella O-
Ags, beginning with the backbone (serotype Y) and the serogroup 2 O-Ags.145 For the 
serotype 2a O-Ag (Figure 5.1b), we found that glucosylation on O-4 of rhamnose C 
(type O-factor II)139 restricted the O-Ag to more compact conformations as compared 
to the highly flexible, unsubstituted serotype Y. Additional substitution on O-3 of 
rhamnose A produced more extended helical conformations, regardless of whether it 
was O-acetylation (serotype 2a, group O-factor 9); or glucosylation (serotype 2b; group 
O-factor 7,8; Figure 5.1c). This work indicated that an O-3-acetylated 2a O-Ag 
(expressing group O-factor 9) may provide stronger cross-protection against 2b 
(ranked 3rd in prevalence, expressing group O-factor 7,8) than 2a (which lacks both O-
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factors) and may provide enhanced coverage of other serotypes expressing O-factor 9 
(serotypes Y1, 1a1, 1b, 5a1, 6, and 7a1).139 
Here we report the next step of our study, modeling the conformations of serotypes 
3a, 3b and serogroup 5. Serotype 3a is a component of the proposed quadrivalent 
vaccine98, 105 as it is prevalent globally98. Serotype 3b is not included in the vaccine, but 
is prevalent in parts of Asia.148, 149 In contrast, serogroup 5 has a relatively low 
incidence of disease; serotype 5a has been widely studied and is used as a reference 
strain, whereas 5b accounted for some cases in the GEMS report.98  
All serotypes in serogroup 3 contain O-acetylation on O-2 of rhamnose C (group O-
factor 6),139 which is important for antibody recognition.150, 151 Serotype 3a (Figure 
5.1d) is defined by additional glucosylation on O-3 of rhamnose A (O-factor 7,8), with 
subtype 3a1 having partial O-acetylation on O-6 of GlcNAc D (O-factor 10, ~40%); 
neither of which are present in serotype 3b (Figure 5.1e).100, 139 Serotype 5a (Figure 
5.1f) is defined by glucosylation at position O-3 of rhamnose B (type O-factor V) with 
subtype 5a1 having partial O-3-acetylation on rhamnose A (group O-factor 9, ~35%).139 
The most common 5a strain for laboratory study (M90T) has no O-acetylation.152, 153 
Serotype 5b (Figure 5.1g) is glucosylated on O-3 of rhamnose A (O-factor 7,8) with no 
O-acetylation.  
Some studies have indicated cross-reactivity between serogroups 2, 3 and 5. Serotypes 
2a, 3b and 5a each react with group O-factor 3,4 antisera (associated backbone 
trisaccharide residues C-D-A)100 and partial cross-reactivity with these strains is 
demonstrated from serotype 2a in human testing.104 Serotypes 2b, 3a and 5b share 




Figure 5.1: Line structures and diagrams of the Shigella flexneri O-antigen repeating 
units of serotypes (a) Y, (b) 2a, (c) 2b, (d) 3a, (e) 3b, (f) 5a, and (g) 5b. All serogroups 
share the serotype Y backbone and are distinguished by substitutions, which are 
labelled with the associated O-factors. Vaccine serotypes 2a and 3a are indicated with 
an asterisk. Schematic diagrams are depicted using the ESN symbol set108 where: green 
triangle - Rha, blue square - GlcNAc, blue circle – Glc, red triangle – O-acetylation.  
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reported from a candidate 2a/3a vaccine against 2b and 5b in guinea pigs.106 
Therefore, a vaccine containing serotypes 2a and 3a (expressing group O-factors 6; 7,8 
and 9) is suggested to elicit broad cross-protection against the remaining serogroup 2, 
3 and 5 serotypes.98 
Here we compare simulations of serogroups 3 and 5 with our recent work on the 
serogroup 2 O-Ags, contrasting the O-Ag behavior for O-acetylated serotype 2a (group 
O-factor 9) and 3a (group O-factors 6 and 7,8) with the non-vaccine serotype 3b (group 
O-factor 6) as well as serotypes 5a (type O-factor V) and 5b (group O-factor 7,8). With 
this large data set for comparison, we aim to broadly identify guiding heuristics for the 
conformational effect of substitutions on particular positions of the Shigella backbone, 
specifically substitutions on rhamnose C (O-factor II in serogroup 2 and O-factor 6 in 
serogroup 3); O-3 of rhamnose A (O-factor 9 in serotype 2a-3Ac; O-factor 7,8 in 
serotypes 2b, 3a and 5b); and O-3 of rhamnose B (O-factor V in serogroup 5). We 
assume that O-factors with a significant conformational effect should be represented 
in the vaccine serotypes to allow for broad coverage. Ultimately, we aim to determine 
whether the conformational findings from our computational modeling supports the 
assumption that a quadrivalent vaccine containing S. flexneri serotypes 2a and 3a (as 
well as 6 and S. sonnei) could provide broad coverage against S. flexneri serotype 3b 
and serogroup 5. 
5.4 Materials and methods 
The S. flexneri O-Ags have glycosidic linkages described by two torsion angles, φ and ψ, 
defined as: φ = H1-C1-O1-Cx’ and ψ = C1-O1-Cx’-Hx’. These definitions are analogous to 
φH and ψH in IUPAC nomenclature and are consistent with our previous glycan 
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modeling.1, 145 This work follows our established methodology for the computational 
study of glycan antigens. Potential of mean force (PMF) calculations for the 
disaccharide fragments of the O-Ag repeating unit indicate the global minima for each 
linkage, which are then used to build short 3 RU chains for initial 300 ns MD 
simulations in solution. The most populated linkage conformations from the 3 RU 
simulations are then used to construct starting structures for the simulations of the 6 
RU chains.2, 124, 154  
5.4.1 φ, ψ PMF calculations 
The low-energy conformations of the glycosidic linkages were determined by 
calculating the potential of mean force (PMF) for rotation about the φ and ψ torsion 
angles of each disaccharide linkage. PMFs were calculated with the metadynamics 
algorithm36 as implemented in NAMD.155 The disaccharide PMFs were calculated in the 
gas-phase with the φ, ψ torsion angles set as collective variables.  
5.4.2 Molecular dynamics 
Simulations were run with the NAMD software package,155 employing CUDA 
extensions to leverage graphics processing units for the calculation of long-range 
electrostatic potentials and non-bonded forces.156 Glycans were modeled with the 
CHARMM36 additive force field for carbohydrates31, 32 and explicit water molecules 
were represented with the TIP3P water model.157 
Our in-house CarbBuilder software was used to build the glycan structures prior to 
simulation.158 Initial 3 RU chains of the serogroup 3 and 5 O-Ags (not discussed here) 
were built with glycosidic linkage conformations set to the energy minimum of the 
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respective disaccharide PMFs. The RUs of the O-Ag chains modeled in this study are as 
follows with the serotype-defining moieties in bold: 
3a:    →2)-[αDGlc(1→3)]αLRha(1→2)-αLRha(1→3)-αLRha2Ac(1→3)-βDGlcNAc-(1→ 
3b:    →2)-αLRha(1→2)-αLRha(1→3)-αLRha2Ac(1→3)-βDGlcNAc-(1→ 
5a:    →2)-αLRha(1→2)-[αDGlc(1→3)]αLRha(1→3)-αLRha(1→3)-βDGlcNAc-(1→ 
5b:    →2)-[αDGlc(1→3)]αLRha(1→2)-[αDGlc(1→3)]αLRha(1→3)-αLRha(1→3)-βDGlcNAc-(1→ 
The 3 RU simulations were run for 1,000 ns and 300 ns (for serogroup 3 and 5, 
respectively), with the most frequent torsion angles from these simulations used to 
build the initial conformations for the 6 RU chains. These conformations were then 
subjected to 10,000 steps of standard NAMD minimization in vacuum and 
subsequently placed into a cubic water box with the solvate command from the Visual 
Molecular Dynamics (VMD) package.159 The cubic water boxes for the 6 RU structures 
had side lengths of 100 Å and 90 Å, respectively, for serogroup 3 and 5, and periodic 
boundary conditions were employed. The solvated structures were gradually heated 
through a protocol of 5 K incremental temperature reassignments between 10 K and 
310 K, with 1,000 steps of NAMD minimization and 1,000 steps of MD after each 
temperature reassignment.  
Equations of motion were integrated using the velocity-Verlet method160 with a 1 fs 
step size. Molecular dynamics simulations were performed under the isothermal-
isobaric (nPT) ensemble at a temperature of 310 K and maintained with a Langevin 
piston barostat155 and Nose-Hoover thermostat – a hybridized method of the Nose-
Hoover constant pressure method161 with piston fluctuations controlled by Langevin 
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dynamics,75 as implemented in NAMD. Particle mesh Ewald (PME) summation76 was 
used for calculation of long-range electrostatics, with k = 0.20 Å-1 and PME grid 
dimensions that were set equal to the periodic cell size. Non-bonded interactions were 
truncated at 15.0 Å and a switching function implemented between 12.0 Å and 15.0 Å. 
1-4 interactions were not scaled, in accordance with CHARMM force field 
recommendations. 
5.4.3 Block averaging analysis 
Block averaging analysis is used to assess simulation convergence and is implemented 
with in-house Python scripts.126 The block averaging analysis algorithm splits a 
simulation trajectory with N frames into a set of M “blocks” with a length of n frames, 
such that N = M x n. Next, an average of a selected measurable (e.g. end-to-end 
distance) is calculated within each block. The block length (n) is slowly increased and, 
at each value of n, the set of block averages are recalculated. The standard deviation in 
the set of block averages, σn, is used to determine the blocked standard error (BSE) for 
each value of n. The simulation is indicated to be converged once the running estimate 
of the BSE asymptotes to a plateau, where the plateau represents the true standard 
error in the estimate of the mean. 35 
5.4.4 Data analysis 
Simulations underwent 200 ns of equilibration followed by production runs of 1 µs and 
2 µs (for serogroup 3 and 5, respectively). Snapshots of molecular conformations were 
taken at 25 ps intervals from the simulation trajectories. Inter-atomic distances and 
torsion angles were measured from VMD’s Tcl console and graphical user interface, 
and statistical calculations were performed with in-house Python scripts. For all 
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saccharides, we defined the end-to-end distance, r, as the length from C-2 of 
rhamnose B at the non-reducing end of the chain and C-1 of rhamnose C at the 
reducing end, thus excluding the very flexible terminal sugar units. 
Molecular conformations were visualized in VMD,159 with carbohydrate rings 
highlighted by the PaperChain visualization algorithm.162 Before conformational 
clustering, the trajectory snapshots were aligned on the ring atoms of the central ‘C-D-
A-B’ fragment between RU3 and RU4 – a frame-shifted full repeating unit to account 
for the variability in each linkage across the different serotypes. The most common 
chain conformations are determined by clustering the simulation snapshots into 
families with relative occupancies. We cluster the central 4 RU of each 6 RU chain, as 
the terminal repeating units are less representative of the native O-Ag backbones. 
VMD’s internal cluster command was employed to calculate the conformational 
clusters in the production runs with an RMSD fit of the non-hydrogen atoms in the 
central 4 RUs with a cut-off of 5.5 Å. Clusters comprising less than 5% of the simulation 
were excluded. The conformations of the previously published serotype Y and 
serogroup 2 simulations145 were recalculated under these criteria for a fair comparison 
between the serogroups.  
5.5 Results 
We begin our analysis of the simulation data with a broad comparison of the O-Ag 
chain extension and flexibility of S. flexneri serogroup 2 with serogroups 3 and 5; then 
we analyze the dominant backbone conformation of each O-Ag; and finally we explore 
the conformational effects of the glucosylation and O-acetylation on the orientations 
of the backbone glycosidic linkages. 
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5.5.1 Simulation convergence 
We used block averaging analysis35, 126 of two metrics of chain flexibility — the end-to-
end distance, r, and the radius of gyration, Rg, — to assess the convergence of the MD 
simulations. Convergence is indicated by the plots of the blocked standard error (BSE) 
for both r and Rg (shown in Figure S5.1a and S5.1b) reaching a plateau. The asymptote 
of the BSE plot represents the true standard error in the measured variable, which can 
be used to approximate a correlation time for the simulation. The range of correlation 
times from 18 ns to 104 ns indicate that the 200 ns equilibration period is sufficient for 
all the O-Ags in this study. Further analysis reveals that the number of statistically 
independent samples in each simulation is much greater than 1 (49, 58, 88 and 21 for 
3a, 3b, 5a and 5b, respectively) - as recommended for a converged trajectory.35 
Therefore, block averaging analysis indicates that the longer production runs (1,000 ns 
for serogroup 3 and 2,000 ns for serogroup 5) provide sufficient sampling of the 
conformational space. The simulations of the more flexible serogroup 5 O-Ags were 
extended to 2 µs to ensure that convergence was achieved.  
5.5.2 O-Ag flexibility 
The fluctuation in r over the course of a simulation is a simple measure of molecular 
extension and flexibility for the S. flexneri O-Ag’s. Here we define r as the distance 
between C-2 of rhamnose B in RU1 and C-1 of rhamnose C in RU6 (Figure 5.2a). Figure 
5.2 compares the r time series and corresponding histograms for the simulations of the 
serotype Y backbone and the serogroup 2 O-Ags previously published145 with 
simulations of serogroup 3 (Figure 5.2f-5.2g) and serogroup 5 (Figure 5.2h-5.2i). 
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For a first broad comparison of the O-Ags, a scan of the graphs in Figure 5.2 quickly 
reveals that the unsubstituted Y backbone (Figure 5.2b) is by far the most flexible of 
the O-Ags, showing the greatest range of r values (σ ≈ 16 Å), whereas the serogroup 2 
O-Ags (Figure 5.2c-5.2e) are the least flexible (σ ≈ 8-9 Å). Serogroups 3 and 5 fall 
between these two extremes, with serogroup 3 being somewhat less flexible (σ ≈ 13 Å 
for 3a, 14 Å for 3b) than serogroup 5 (σ ≈ 14 Å for 5a, 15 Å for 5b). Moreover, the 
distributions of r vary considerably across the O-Ags. The flexible serogroup Y has a 
bimodal distribution, in stark contrast to the well-defined tight distributions shown for 
serogroup 2.  
The graphs of r reveal that the effect of glucosylation on the conformation and 
dynamics of the O-Ag chain depends on the glucosylation position: compare the graph 
of serotype 2a expressing O-factor II (O-4 glucosylation on rhamnose C, Fig 5.2c) with 
5a expressing O-factor V (O-3 glucosylation on rhamnose B, Figure 5.2h). In particular, 
the O-factor II glucosylation that defines serogroup 2 has a very dramatic effect on r, 
reducing the overall extension and flexibility of the chain. In contrast, the O-factor V 
glucosylation that defines serogroup 5 has a less obvious effect on r, slightly increasing 
the average chain extension. Finally, O-factor 7,8 (O-3 glucosylation on rhamnose A; 
serotypes 2b, 3a and 5b) appears to narrow the distribution of r, making the O-Ag 
chains more conformationally defined. For example, there is a clear difference in the 
shape of the r distribution for serotype 3a (Figure 5.2f) as compared to 3b (Figure 
5.2g): serotype 3a has a unimodal distribution of r (mean 45 Å, σ ≈ 13 Å) whereas in 3b 
(which lacks O-factor 7,8) r is shifted to smaller values and has a right-skewed 
distribution with a peak at 25 Å (mean 29 Å, σ ≈ 14 Å). This significant shift in r  
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Figure 5.2: Comparison of the r time series and corresponding histograms for 6 RU 
simulations of the modeled S. flexneri O-Ags. (a) A 6 RU model of the serotype Y O-
Ag depicted with the end-to-end distance, r; rhamnose is colored pink and N-acetyl-
glucosamine blue. The r time series (left column for each serotype) and 
corresponding distribution (right column for each serotype) are shown for (b) Y, (c) 
2a, (d) O-3 acetylated 2a, (e) 2b, (f) 3a, (g) 3b, (h) 5a and (i) 5b. The mean for each 
histogram distribution is depicted with a dashed line and the corresponding 
standard deviation is indicated. 
   
119 
 
distribution within serogroup 3 indicates a substantial conformational difference 
between the 3a and 3b O-Ags, and hence a significant conformational effect for O-
factor 7,8. We have previously observed the same effect in serogroup 2 and it can be 
observed within serogroup 5, which is the least conformationally defined of the four 
serogroups. Serogroup 5 is the most similar to the Y backbone, but does not show the 
same clear bimodal distribution. The r distributions for serotype 5b (expressing O-
factor 7,8) show a slight shift to more extended conformations (Figure 5.2i) as 
compared to 5a (Figure 5.2h). However, the similarity of the r distributions for 5a and 
5b suggest similar conformational behavior for both serotypes.  
Further, a comparison of the r histograms can reveal the general effects of O-
acetylation on the O-Ag backbone. We have previously observed that O-factor 9 (O-
acetylation at O-3 of rhamnose A, serotype 2a-3Ac) has a similar conformational effect 
to glucosylation at this position (O-factor 7,8, serotype 2b), reducing the range of r. 
The range restriction for O-acetylation is not as dramatic as with glucosylation, which is 
expected from the relative size of the substituents (Ac = 43 g/mol and Glc = 179 
g/mol). More surprisingly, we now see that O-factor 6 (O-acetylation at O-2 of 
rhamnose C, serogroup 3) has a similar effect restrictive effect on r, as can be seen in a 
comparison of serotype 3b (Figure 5.2g) with the backbone serotype Y (Fig 5.2b). 
A general comparison of the r histograms suggests three broad heuristics for the 
effects of substitution on the backbone (serotype Y) conformation of the Shigella O-
Ags. First, substitution at rhamnose C (O-factor II in serogroup 2 and O-factor 6 in 
serogroup 3) has the most impact in reducing the flexibility and extension of the O-Ag 
chain, with glucosylation (2a) having a greater impact than O-acetylation (3b). The 
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impact of substitution on rhamnose C on O-Ag conformation is supported by the fact 
that O-factor II defines serogroup 2 and O-factor 6 is present in all of serogroup 3. 
Second, any substitution on O-3 of rhamnose A (O-factor 9 in serotype 2a-3Ac; O-
factor 7,8 in serotypes 2b, 3a and 5b) shifts the O-Ag to more extended conformations. 
Third, O-factor V (substitution at O-3 of rhamnose B, serogroup 5) does not have a 
significant effect on chain conformation. Our analysis suggests that, at a first 
approximation, these three heuristics are additive. To test and refine these rules of 
thumb, as well as investigate the potential for cross-reactivity between serotypes, we 
now perform a detailed comparison of the chain conformations for all O-Ags. 
5.5.3 O-Ag chain conformations 
Figure 5.3 compares the conformational families for serotype Y (Figure 5.3a) and the 
serogroup 2 O-Ags (Figure 5.3b-d) with the serogroup 3 (Figure 5.3e and f) and 
serogroup 5 (Figure 5.3g and h) O-Ags. As discussed in prior work,145 the flexible Y 
backbone transitions between extended conformations (Figure 5.3a Y-1, Y-4 and Y-6) 
to more curved arrangements of the chain (Figure 5.3a Y-2, Y-3 and Y-5). Further, we 
showed that O-factor II (O-4 glucosylation at rhamnose C, serogroup 2) has a dramatic 
effect on the chain conformations, removing the extended conformations and 
restricting the O-Ag to a wide range of “C-curves” (Figure 5.3b). Additional substitution 
on O-3 of rhamnose A - whether O-acetylation in 2a (O-factor 9) or glucosylation in 2b 
(O-factor 7,8) was then shown to further restrict the chain and induce helical 
conformations (compare Figure 5.3c and d). 
In common with serogroup 2, serogroup 3 is also substituted at rhamnose C, albeit 
with a smaller O-acetyl group at position 2 (O-factor 6). A comparison of the dominant 
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conformations of 2a (Figure 5.3b) and 3b (Figure 5.3f) reveals that O-factors 6 and II 
have a similar effect on the backbone. For the 3b O-Ag, O-2-acetylation on rhamnose C 
removes most of the extended conformations of the chain and restricts the O-Ag to a 
range of C-curve conformations (3b-1) and other folded conformations of the chain 
(3b-2, 3b-4 to 3b-7). The dominant curved chain conformation for 2a (2a-1, 31%) and 
3b (3b-1, 11%) are remarkably similar, indicating a similar conformational effect of 
substitution at rhamnose C. However, the smaller O-acetyl substituent means that the 
3b chain remains more flexible than the 2a and has a minor helical conformational 
family (3b-3, 7%).  
As for serotype 2b, serotype 3a is substituted at rhamnose C as well as rhamnose A (O-
factor 7,8). This combination of substitutions has a similar effect on the conformation 
of the 3a O-Ag (Figure 5.3e) as it does on 2b (Figure 5.3d), producing a dominant 
helical conformation with 3 RU per turn and an average pitch of 29 Å (3a-1, 11%). 
However, 3a remains more flexible than 2b and can adopt a wide range of helical 
conformations (3a-3, 3a-5), as well as partially extended chains (3a-2), fully extended 
chains (3a-4) and S-bends (3a-6). Therefore, the serogroup 3 O-Ags follow a similar 
trend to serogroup 2145: substitution on rhamnose C restrict the chains to curved 
conformations for both serotype 2a and 3b (Figure 5.3b and 5.3f) and additional 
substitution on O-3 of rhamnose A shifts the conformations towards helices for 
serotypes 2a-3Ac, 2b and 3a (Figure 5.3c, 5.3d and 5.3e). Further, the axially orientated 
O-acetyl groups of serogroup 3 are readily accessible for antibody binding in both 
serogroup 3 O-Ags, which supports the reported immunodominance of O-factor 6.150 
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Figure 5.3: Conformational families of the central 4 RU of the 6 RU chains for (a) Y, 
(b) 2a, (c) O-3-acetylated 2a, (d) 2b, (e) 3a, (f) 3b, (g) 5a, and (h) 5b. Relative 
occupancies in the simulations (excluding the initial 200 ns) are indicated as 
percentages. Clusters of less than 5% are not shown. The sugars are colored: pink 






A comparison of the primary conformations of serogroup 5 with the backbone shows 
the effect of O-factor V (glucosylation at O-3 of rhamnose B) on the chain 
conformation. Relative to the backbone (Figure 5.3a), the 5a O-Ag shows an increase in 
the prevalence of elongated helices (Figure 5.3g): the dominant conformation (5a-1, 
25%) is a right-handed helix with 3 RU per turn, in agreement with an early helical 
model prediction.127 This extended helical structure (pitch of 30 Å) has significant 
flexibility - the helix encompasses just 25% of the simulation and frequently unwinds to 
extended chains (5a-2 and 5a-4) as well as C-curve conformations (5a-3 and 5a-5) that 
are also present in the backbone (e.g. Y-4 and Y-5). Therefore, O-factor V has only a 
slight impact on the backbone conformation. However, the glucose side chains 
(colored cyan in Figure 5.3g and h) are exposed for antibody binding. 
Serogroup 5b adds O-factor 7,8 (glucosylation on O-3 of rhamnose A) which, according 
to our heuristic hypothesis, should have a similar effect as in serogroup 2, increasing 
the dominance of helices in the 5b O-Ag conformations. This is in fact the case: 
although the 5b O-Ag has a similar dominant conformational family (Figure 5.3h, 5b-1, 
24%) to 5a, the more minor C-curve conformations in 5a are replaced with helices in 
5b (5b-2, 13%; 5b-4, 7%). The chain also has a unique tight hairpin bend conformation 
(5a-3, 11%) corresponding to the short r values adopted early in the 5b r time series 
(Figure 5.2i).  
In summary, conformational analysis suggest refinement of our proposed three broad 
heuristics for the effects of substitution on the backbone conformation of the Shigella 
O-Ags, as follows. First, substitution at rhamnose C (present in serogroups 2 and 3) 
restricts the O-Ag chain to predominantly curved conformations, with a larger 
124 
 
substituent (e.g. O-4 glucosylation in serogroup 2) having a greater effect than a 
smaller one (e.g. O-2 O-acetylation in serogroup 3). Second, additional substitution on 
O-3 of rhamnose A (be it O-acetylation or glucosylation: 2a-3Ac, 2b, 3a, 5b) restricts 
the O-Ag to helical conformations. Third, substitution at O-3 of rhamnose B (O-factor 
V, serogroup 5) has only a slight effect on conformation, shifting the backbone to 
somewhat more extended O-Ag conformations. To explain the origin of these general 
effects, we now investigate the impact of the substitutions on the constituent 
glycosidic linkages in the S. flexneri O-Ag repeating unit. 
5.5.4 O-Ag glycosidic linkage conformations 
As carbohydrate rings have fairly constrained chair conformations, chain flexibility in 
the S. flexneri O-Ags arises principally from rotations about glycosidic linkages, which 
are commonly measured via the φ and ψ torsion angles. Ring substitutions can 
increase or, more commonly, decrease, the range of motion for a glycosidic linkage. 
The range of motion for each of the glycosidic linkages in the serogroup 3 and 5 O-Ag 
RUs over the course of the simulations is shown in Figure 5.4 with scatter plot 
heatmaps of the φ, ψ torsion angle distribution over the course of the simulations. 
Fragments of the O-Ag backbone showing the relative arrangements of the sidechains, 
the N-acetyl (blue) and the O-acetyl (red) substituents for each of the serotypes are 
shown in Figure 5.5. 
For the Y-backbone (Figure 5.4a), the φ torsion angle for all linkages is restricted to a 
narrow range of values around φ ≈ 40°, whereas the ψ torsion angle is more flexible 
with two primary conformations at ψ ≈ 10° and ψ ≈ -35° (hereafter referred to as +ψ 
and –ψ, respectively). The D-A linkage is the most constrained, having the narrowest 
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range for psi, because the close proximity of the N-acetyl group to this β-D-GlcpNAc-
(1→2)-α-L-RhapIII linkage restricts ψ rotations. The backbone torsion angle 
conformations are consistent with the scatter plots of the φ, ψ linkages from short (60 
ns) simulations of 3 RU chains.146 Further, the estimates of key NOE distances (by r6 
averaging) are in good agreement with NMR NOE measurements for the native LPSs of 
serotype 3a146 (Supp. Table S5.2) and 5a127 (Supp. Table S5.3), providing validation for 
our MD simulations.163  
Comparison of the heatmaps for substituted O-Ags with the backbone (serotype Y) 
maps allows a closer identification of the specific effect of substitutions on the O-Ag 
local chain flexibility and dynamics.  
For the first heuristic, we have found that substitution at rhamnose C (serogroups 2 
and 3) restricts the extension of the O-Ag chain to predominantly curved 
conformations. Comparison of the φ, ψ heatmaps for the Y backbone (Figure 5.4a) 
with those for serogroup 2 (Figure 5.4b-d) shows that the B-C glycosidic linkage (α-L-
RhapII-(1→3)-α-L-RhapI) is considerably restricted in serogroup 2 as compared to the 
unsubstituted backbone. Serogroup 2 is glucosylated at O-4 of rhamnose C (O-factor 
II); steric hindrance by this glucose side chain restricts the range of freedom in the 
neighboring ψ torsion angle of the α-(1→3) B-C linkage – see Figure 5.5a-c. Serogroup 
3 (Figure 5.4e and f) shows a lesser restraint on the B-C linkage, but the α-(1→3) C-D 
linkage is also restricted relative to the backbone. Serotype 3 is O-2-acetylated on 
rhamnose C (O-factor 6), and the O-acetyl group is in close proximity to the N-acetyl 
group of D (β-D-GlcpNAc), as shown in Figure 5.5d and e. Transient hydrogen bonding 
of the carbonyl oxygen with the hydrogens on the neighboring N-acetyl amplify the 
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restrictive effect of the O-acetylation: the C-D linkage for serotype 3b is constrained 
with partial access to –ψ conformations (mean ≈ -12°) and glucosylation on rhamnose 
A (O-factor 7,8) further limits the C-D linkage to +ψ orientations for serotype 3a (mean 
≈ -6°). It is interesting that a similar restriction in either of these α-L-Rhap-(1→3) 
linkages (B-C and C-D) to –ψ angles has a similar conformational effect for the 
serogroup 2 and 3 O-Ags, reducing the extension of the O-Ag chain. In contrast, the 
serogroup 5 O-Ag B-C linkages remain unconstrained, adopting predominantly +ψ 
orientations (mean ≈ 7°) that result in a greater prevalence of extended structures 
despite glucosylation on O-3 of rhamnose B (O-factor V). This accounts for the more 
extended helical conformation in our molecular dynamics simulations as compared to 
the static model which was built with –ψ B-C orientations.127 
In contrast, the α-L-RhapIII-(1→2)-α-L-RhapII linkage (A-B) is flexible across all 
serogroup 2, 3 and 5 O-Ags (Figure 5.4, first column), significantly contributing to the 
conformational flexibility of the O-Ags. For serogroup 2, the linkage shifts to favor –ψ 
orientations (increasing the prevalence of C-curve conformations) while the serogroup 
3 A-B linkages remain largely unchanged compared to the backbone (serotype Y). 
Inspection of the backbone fragments in Figure 5.5 shows that the glucose substituent 
on O-4 of rhamnose C is in closer proximity to the A-B linkage than the less bulky O-
acetyl substituent at the O-2 position. For serogroup 5, the adjacent glucose side-chain 
on O-3 of rhamnose B does impose a small steric hindrance to the A-B linkage, possibly 
contributing to extension of the O-Ag chains in this serogroup.  
For our second heuristic, we found that further substitution on O-3 of rhamnose A 
shifts the O-Ag to extended helical conformations. Comparison of the heatmaps for   
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Figure 5.4: Heat map representations of scatter plots for the φ, ψ torsion angles of 
each glycosidic linkage for serotypes (a) Y, (b) 2a, (c) 2a-3Ac, (d) compared to serotypes 
(e) 3a, (f) 3b, (g) 5a and (h) 5b in this study. The heat maps combine the points from 
both central repeating units (RU 3 and RU 4) to broadly sample backbone behavior. The 







2b (Figure 5.4d), 3a (Figure 5.4e) and 5b (Figure 5.4h) with the serotype Y backbone 
shows that glucosylation at this position (O-factor 7,8) significantly reduces the range 
of motion for the ψ torsion angle of the D-A β-D-GlcpNAc-(1 →2)-α-L-RhapI linkage 
from two dominant conformations at ψ ≈ 15° (+ψ) and ψ ≈ -45° (-ψ) to a single 
dominant conformation at ψ ≈ 12°. In combination with -ψ orientations for the A-B 
and B-C linkages, this induces a primary helical conformation for serotype 3a. The 
glucose side-chain (residue F) is in close proximity to the N-acetyl group of the 
adjacent D residue (β-D-GlcpNAc), as shown in Figure 5.5c and d. Steric clashes 
between the glucose substituent and the N-acetyl group hinders rotation around the 
D-A linkage and reduces chain flexibility. The α-D-Glcp-(1→3)-α-L-RhapIII side chain (F-
A, Figure 5.4, fifth column) is in turn also restricted by the N-acetyl moiety with a single 
conformation at φ, ψ ≈ -52°, -36°, which is in agreement with NMR measurements for 
short serotype 3a fragments that predict a –ψ orientation.150 
O-acetylation at this position (O-factor 9, serotype 2a-3Ac, Figure 5.4c) has a lesser, 
but similar, restriction on the range of rotation. Steric clashes between these two 
groups explain the large conformational restriction produced by glucosylation 
(serotypes 2b and 3a) as well as O-acetylation (2a-3Ac, Figure 5.5b) on rhamnose A. 
The conformational effects of this restraint are to increase the incidence of more 
regular helical structures in these serotypes.  
Finally, for the third heuristic, we found that substitution at O-3 of rhamnose B (O-
factor V, serogroup 5) has only a slight effect on conformation, shifting the backbone 
to somewhat more extended O-Ag conformations. Comparison of the heatmaps for 
serogroup 5a (Figure 5.4g) with the backbone shows that glucosylation at this position  
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Figure 5.5: Fragments of the backbone showing the relative arrangements of the 
sidechains, the N-acetyl (blue) and the O-acetyl (red) substituents for serotypes (a) 





has little effect on the backbone A-B and B-C linkages: the glucose side chains do not 
interfere with rotations about the bonds (Figure 5.5f and g). 
5.6 Discussion 
Our simulations show that S. flexneri serogroups 2, 3 and 5 all have very flexible O-Ags. 
However, substitutions of the backbone residues limit the range and distribution of 
chain conformations in different ways. Our analysis has suggested three broad 
heuristics for the effects of substitution on the backbone conformation of the Shigella 
O-Ags: (1) substitution on rhamnose C has the greatest impact on restricting the 
extension and conformational range of the O-Ag’s; (2) substitution at O-3 of rhamnose 
A (2a-3Ac, 2b, 3a, 5b) also has a strong impact, restricting the O-Ag’s to predominantly 
helical conformations; (3) substitution at O-3 of rhamnose B (serogroup 5) has only a 
slight effect on conformation.  
Can this conformational analysis give some insight into whether a quadrivalent vaccine 
containing S. flexneri serotypes 2a, 3a (as well as 6 and S. sonnei) could provide broad 
coverage against S. flexneri serotypes 3b, 5a and 5b? The factors that lead to cross-
protection between O-Ags are not well understood. However, an assumption that 
similar O-Ag conformations is a necessary (if not sufficient) criterion for cross-
protection between O-Ag’s seems reasonable. However, immunodominant 
substitutions that change the binding surface (but perhaps not the conformation) may 
be confounding factors. On a conformational basis, we postulate that the two 
substitutions that produce the greatest conformational effects should be represented 
in the vaccine serotypes. Therefore, the vaccine should contain serotypes with 
substitutions on rhamnose C (O-factors II and 6) as well as rhamnose A (O-factors 9 
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and 7,8). Inclusion of an additional serotype with substitution at rhamnose B (O-factor 
V) seems less likely to be necessary. On the basis of this argument, the 2a-3Ac serotype 
containing both O-factors II and 9 would seem to be sufficient, whereas 2a (only 
substituted on rhamnose C) would not. 
Cross-protection within serogroup 2 (2a-3Ac and 2b) seems likely due to the similar 
helical conformations of the serotypes within the group, and cross-protection with the 
helices in serogroup 3 and serogroup 5 may be possible. However, this conformational 
argument does not consider serogroup 3’s immunodominant O-2-acetylation on 
rhamnose C (O-factor 6),150, 151 which is a strong basis for including this serotype. 
Further reasons to include 3a are the prevalence of 3a infection, the lack of expected 
cross-protection from 2a164-166 and potential cross-protection by 3a against 2b arising 
from the shared glucosylation of rhamnose A (O-factor 7,8). Although serotype 3b is 
conformationally more similar to the non-acetylated 2a chain, the minor C-curve and 
helical conformations of 3b may allow for partial cross-reactivity from a 2a-3Ac vaccine 
component. Further, serotypes 3a and 3b share minor conformational families, which 
may be sufficient to elicit cross-reactivity. Furthermore, serogroup 3a may provide 
cross-reactivity with other disease-causing serogroups: serotypes 1b and 4b express O-
factor 6 and serotype X expresses O-factor 7,8.  
5.7 Conclusion 
On the basis of conformational similarity, we suggest that the inclusion of serogroup 5 
is not necessary in the vaccine, as serotype 5a shares similar helical structures with the 
2a-3Ac chain. Further, the partial O-acetylation on O-3 of rhamnose A (O-factor 9) for 
serotype 5a could provide cross-reactivity with an O-acetylated serotype 2a vaccine, 
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although the exposure of the O-factor V glucosylation for antibody binding may be a 
confounding factor. In future work, we will investigate the O-Ags of the next most 
prevalent serogroups identified by the GEMS report – serogroups 6 and 1 – to allow for 
further development of our heuristics for the conformations of the S. flexneri O-
antigens. 
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Supplementary Figure S5.1: Block averaging analysis for the (a) end to end distance, 
r, and (b) radius of gyration for 6 RUs of the serogroup 3 and 5 O-Ags. The plot of 
blocked standard error (BSE) versus block size reaches a plateau for all the O-Ags of 
serogroup 3 and 5, indicating convergence in each simulation.  





Supplementary Table S5.2: Comparison between MD simulation and experimental 
data of distances between hydrogen atom pairs (columns) are in good agreement 
for serotype 3a. (a) The mean distance and corresponding r6 average from our 1.2 
µs production runs, excluding 200 ns for equilibration. (b) Experimental NMR 
distances from NOE build-up curves (estimated 10% error) and distances calculated 
by full ensemble relaxation analysis of 60 ns MD simulations of a 3RU serotype 3a O-





Supplementary Table S3: Distances of pairs of hydrogen atoms (columns) from MD 
simulation and experimental data for serotype 5a. (a) The average distance and 
corresponding r6 average from our 2 µs production runs, excluding 200 ns for 
equilibration. (b) Experimental NMR distances (estimated 10% error) derived from 
NOE build-up curves and ROESY off-resonance measurements (Clement et. al., 
2003). (c) Distances calculated by full ensemble relaxation analysis of 60 ns MD 






Discussion and conclusions 
This dissertation employed molecular dynamics simulations to investigate the 
polysaccharide antigens of prevalent disease-causing N. meningitidis serogroups and S. 
flexneri serotypes to promote a rational basis for vaccine strain selection. The 
computational modeling in this work provides detailed descriptions of the dynamic 
motion of glycan chains at the molecular scale and identifies the effects of substitution 
on backbone conformation in chemically similar glycan chains. This theoretical 
understanding of glycan antigen conformations aims to guide the design and 
composition of future glycoconjugate vaccines against these pathogens.  
Our methodology characterizes glycan conformations with molecular dynamics using 
an incremental approach - beginning with brief simulations of short chains and 
building up to extended chains with long production runs. This approach produces 
initial glycan structures with low-energy conformations and, therefore, the simulation 
trajectory is likely to converge quickly and explore the most prevalent conformations 
of the native glycan chains in solution.  
The computational methodology in each study made use of a set of metrics to 
characterize and compare the dynamic behavior of each glycan chain. The end-to-end 
distance is a simple metric that gives a broad overview of relative chain extension and 
flexibility. Clustering analysis then reveals specific detail of overall glycan chain 
behavior by grouping snapshots of the glycan chain over the simulation trajectory into 
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conformational families. Although the mechanisms of antigen cross-protection are not 
well understood, it seems reasonable to assume that similarity in chain conformation 
is required, considering the role of antigen-binding to cross-protective antibodies in 
the immune response. It is on this conformational basis that theoretical insight can be 
gleaned to guide vaccine composition and design. Finally, we investigate a rationale for 
the specific structural consequences of chemical alterations in a glycan RU through 
analysis of each glycosidic linkage. As the majority of glycan motion arises from 
transitions in the glycosidic bond orientations, scatter plots of the linkage torsion 
angles over the simulation trajectory can uncover subtle mechanistic details and 
atomic interactions that contribute to the differences observed in overall chain 
conformation. This specific detail can identify targets for synthetic chemical alterations 
of a native RU in the development of antigen mimics that maintain conformational 
similarity. 
Each individual metric supplies partial insight into the flexibility of a glycan antigen, 
however, combined they provide a thorough theoretical characterization of the overall 
conformational behavior. The comparative methodology employed in this work – 
juxtaposing chemically similar glycan chains under identical simulation conditions - is 
powerful in highlighting relative conformational differences in preferred chain 
conformations and provides a rational basis for vaccine antigen selection - including in 
the absence of experimental data.  
If limited or no experimental data is available, alternative statistical methods can be 
employed to validate simulation data and subsequent conformational findings. For 
example, to compensate for the lack of substantial experimental findings for Shigella 
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cross-protection in human studies, we undertook additional statistical analysis (block 
averaging analysis) to evaluate the extent of conformational sampling in each 
simulation and the sufficiency of the chosen equilibration time. Further, these 
statistical measures proved useful to inform decisions relating to simulation length - 
whether extension was required or if simulation convergence had occurred and 
analysis could therefore begin. Assessment of the statistical fitness of a data set is an 
important additional step to include in our systematic methodology for the robustness 
of future modeling studies, even when experimental data is available for 
corroboration.  
It should be emphasized that combining all available data - both theoretical and 
experimental - is the most powerful approach to building a holistic understanding of 
carbohydrate conformation and antigen cross-protection. For instance, computational 
modeling alone cannot account for confounding immunological phenomena such as 
immunodominance, where the strength of an immune response varies for specific 
epitopes. However, insight from MD remains crucial to the understanding of glycan 
antigens as empirical findings specifically investigating serotype conformation or cross-
protection tend to be uncommon and experimental data (e.g. X-ray crystallography 
and NMR) only provides limited descriptions of dynamic motion.  
While static glycan X-ray crystal data can allow for construction of three-dimensional 
models, the insight is limited as it does not reveal the extent of possible dynamic 
motion or indicate structural features arising from constraints in the crystal lattice that 
might not be present in solution. However, this technique can provide important 
insights into the relative sizes of polysaccharide epitopes, which can inform future MD 
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simulations. Furthermore, bound antibody-antigen crystal structures, if available, can 
still be particularly useful in revealing important binding modes and corroborating 
unusual linkage conformations such as for the branching glucose of S. flexneri serotype 
2a described in chapter 4. Unfortunately, glycan crystal structure data is rare due to 
challenges in the crystallization of carbohydrates. 
Multiple NMR techniques are available that each provide partial insight into molecular 
conformation. NOE correlations, arising from the transferal of magnetization of close-
contact spin-active nuclei in NMR experiments, are a common source of experimental 
corroboration for predicted structures. However, computational models of glycan 
conformations are still required to contextualize this experimental data as NOE values 
only arise over short atomic distances (< 5 Å), which typically provides insufficient 
correlations to identify a specific chain conformation.  
Another conformational insight provided by NMR is the three-bond coupling (J3) 
between spin-active nuclei, which correspond to an estimated torsion angle via a 
Karplus equation that is parameterized according to the identity of the atoms involved 
in bonding. While the coupling constant can be measured very accurately, the 
calculation of the corresponding torsion angle is ambiguous as the sinusoidal nature of 
a Karplus equation relates each coupling constant to multiple possible torsion angles. 
However, these coupling constants still allow for the exclusion of accessible regions on 
a phi/psi plot and can be compared to the predicted average from MD simulations for 
model validation. 
A more recently developed technique, is to measure residual dipolar couplings (RDCs) 
for relatively rigid structures, which provides complementary conformational data to 
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NOEs and J3 coupling. By disturbing the isotropic nature of a solution through the 
addition of a solute that aligns with the external NMR magnetic field, RDCs can be 
measured from NMR spectra. The RDCs encode the orientation of specific atom pairs 
relative to the external magnetic field. With an r3 distance dependence, RDCs can also 
be measured over much longer distances than NOEs, which arise from an r6 distance 
dependence. Provided sufficient sample is available for the multiple experiments 
required, RDCs have proven a powerful tool in protein research.167 
However, conformational insights from NMR have inherent ambiguity as the 
experimental data can only represent the average molecular conformation in solution 
and can be misleading if the molecule is particularly flexible. A measurement arising 
from a relatively static molecular interaction is indistinguishable from a measurement 
representing the weighted average of a pair of atoms with significant molecular 
motion. For this reason, NMR data frequently yields measurements for use as restraint 
data in structural refinement but is limited in revealing dynamic motion without a 
computational model for context. Therefore, MD provides unique insight into dynamic 
molecular motion, while experimental methods tend to play a larger role in the testing 
and validation of the MD simulations.  
The central insight from this computational work are descriptions of the range of 
preferred glycan antigen conformations and their relative occupancies (corresponding 
to the energetic stability) that rationalize and predict antigen cross-protection. MD can 
investigate further pertinent questions for vaccine development in collaboration with 
experiment. For instance, optimal chain length is a particularly important 
consideration for vaccines composed of synthetic glycans: a shorter chain length 
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affords less complex synthesis and improved yields but may not elicit an immune 
response that will recognize the longer chains of the native antigen. While the immune 
response is inherently an empirical finding, our incremental MD methodology is well 
suited to highlighting changes in glycan conformation as a function of length, as 
illustrated in the modeling of N. meningitidis glycan antigens in chapters 2 and 3. 
Likewise, molecular dynamics can provide complementary understanding of 
antigenicity findings by investigating the solvent accessibility of specific epitopes (e.g. 
O-acetylation in N. meningitidis and S. flexneri) as well as the conformations of antigen 
mimics, as presented in this body of work. By first investigating these phenomena 
computationally, laboratory time can be focused towards the most relevant areas for 
experimental investigation, optimizing laboratory resources.  
A weakness of the MD methodology is the time intensive nature in computing 
simulation data sets of sufficient length, which depends on the level of detail required 
and the computational power available. This limitation can be mitigated by employing 
further ‘coarse-grained’ approximations to reduce computation time and by planning 
experimental studies to run in parallel with computational experiments. However, 
obtaining computational insight in a timely manner remains an important barrier to 
the more wide-spread adoption of molecular dynamics simulations. Nevertheless, 
molecular modeling continues to contribute key understanding of dynamic glycan 
conformations, both complimenting experimental investigation and as a standalone 
methodology.  
Overall, the multiple case studies of glycan antigen conformations presented in this 
work describe multiple examples of key theoretical insights provided by MD 
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simulations that are typically inaccessible to direct empirical study. These 
investigations develop cross-protection rationale based on conformational analysis, 
identify mechanisms inducing conformational change from chemical alterations in a 
RU, discern dependence of conformational behavior on antigen chain-length and 
reveal the solvent accessibility of immunologically important epitopes. Specifically, our 
findings rationalize the cross-protection data available for N. meningitidis serogroups A 
and X and has a more predictive role for the expected cross-protection between S. 
flexneri O-Ags, resulting in recommendations for the design of vaccines against each 
pathogen. Ultimately, the significant explanatory power of the computational 
methodology employed in these studies promotes and builds a rational basis for glycan 
vaccine design instead of the empirical ‘trial-and-error’ approach of decades past. 
The first pair of publications consider the antigens of N. meningitidis serogroup A and X 
with CPSs consisting of phosphodiester-linked monosaccharide RUs. The first study 
compared the conformations of oligosaccharide chains of meningococcal serogroup A 
and X, which differ in RU linkage position and N-acetyl orientation at C-2 (1->6 linked 
ManNAc and 1->4 linked GlcNAc for A and X, respectively). Serogroup X was found to 
adopt helical epitopes that were corroborated by key NMR NOESY correlations. By 
contrast, the five-bond α(1->6) linkage of serogroup A had significant flexibility with 
random-coil behavior, as exhibited in the wide array of conformational families.  
Investigation of chemical substitutions to the serogroup A RU found notable shifts in 
conformation relative to the unsubstituted backbone. Firstly, O-acetylation on the 
native serogroup A chain causes a significant straightening effect, inducing rigidity in 
the highly flexible backbone. Secondly, a serogroup A mimic (with substitution of the 
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ring-oxygen for a methylene group) was found to maintain considerable chain 
flexibility, however, the chemical alteration induced significant localized 
conformational differences that inhibited S-bend conformations in the carba-MenA 
mimic that were present in the native MenA chain.  
These noteworthy findings of conformational differences in N. meningitidis antigens 
relative to the serogroup A chain provides guidance for the composition of future 
multivalent meningococcal vaccines: 1) A serogroup A vaccine is recommended to 
possess O-3-acetylation. The native antigen is O-3-acetylated (70% - 95%), which we 
find causes a pronounced straightening effect in the serogroup A chain conformation. 
This supplies corroboration for the requirement of O-acetylation (> 61.5%) in 
serogroup A vaccines because a vaccine with the same dominant conformation as the 
native antigen is likely to provide optimal protection. 2) A carba-MenA mimic, despite 
increased chemical stability, is unlikely to provide strong cross-protection against 
serogroup A and is not recommended as a replacement serogroup A vaccine candidate 
due to the significant localized conformational differences. 3) Serogroup X is 
recommended to be included as a distinct component in the next generation of 
vaccines to ensure broad coverage against meningococcal infection. Despite both 
serogroup A and X consisting of phosphodiester-linked monosaccharide RUs, the lack 
of conformational similarity arising from differing linkage positions suggests that little 
or no cross-protection will occur from serogroup A vaccination. 4) Based on literature 
studies on 1 RU and our work on 2 RUs and 6 RUs, meningococcal serogroup A and X 
glycan vaccine components should consist of longer chains (approximately ≥ 6 RUs) as 
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the conformations of the shorter glycan chains are not found to be representative of 
the conformations of the longer native CPS chains. 
The final two papers explore the potential for cross-protection between S. flexneri 
serotypes to guide current development efforts towards an envisioned broad-coverage 
multivalent Shigella vaccine with minimal valency. As each strain shares the same  
→2)-α-L-RhapIII-(1→2)-α-L-RhapII-(1→3)-α-L-RhapI-(1→3)-β-D-GlcpNAc-(1→ backbone 
(residues A-B-C-D), cross-protection between strains is expected; however, only 
limited clinical cross-protection data is available to illustrate this. The third publication 
in this dissertation investigates the conformations of the most prevalent Shigella 
strains – the serogroup 2 O-Ags - as well as the unsubstituted serotype Y backbone. 
The investigation found the serotype Y backbone to be highly flexible, while the 
serogroup defining glucosylation of serotypes 2a and 2b significantly constrains 
backbone motion to C-curves and helices, respectively. Most significantly, the study 
discovered that an O-3-acetylated serotype 2a chain shares conformational features 
with both serotypes 2a and 2b, acting as a conformational hybrid between the two 
prevalent infectious serotypes. This suggests that an O-3-acetylated 2a vaccine could 
function as an optimized antigen in a first Shigella vaccine, allowing for broad 
serogroup 2 cross-protection from a single vaccine component. 
The fourth and final publication expanded the study of S. flexneri O-antigens by 
considering the glycan RUs of serogroups 3 and 5, in addition to the previous 
serogroup 2 findings, within the context of a proposed broad-coverage vaccine 
containing serotypes 2a and 3a. This broad investigation of Shigella O-Ags found 
guiding heuristics for the effects on backbone conformation by substitution at varying 
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positions in the O-Ag backbone RU. First, substitution on rhamnose C, whether O-4-
glucosylation (serotype 2a) or O-2-acetylation (serotype 3a), had the most significant 
effect on chain conformation - restricting the glycan chain in both cases to 
predominantly C-curves conformational families. Second, O-3-glucosylation on 
rhamnose A (serotypes 2a-3Ac, 2b, 3a and 5b) restricts the chain to predominantly 
helical conformations through steric interaction with the adjacent glucose-N-acetyl 
residue. Thirdly, O-3-glucosylation on rhamnose B (serogroup 5) has only a minor 
effect on O-Ag conformation.  
These studies on the conformations of immunologically important Shigella O-antigens 
provide predictive insight into potential cross-reactivity from an anticipated 
multivalent Shigella vaccine (containing serotypes 2a, 3a, 6 and S. sonnei) as well as 
provide recommendations for the composition of such a vaccine, as follows: 1) A 
serotype 2a component should include O-3-acetylation on rhamnose A – in addition to 
direct coverage of the dominant strain causing S. flexneri infection (2a), the helical 
conformation would likely provide increased serotype 2b cross-protection and 
potential broader serogroup coverage through shared helical conformations in 
serogroups 3 and 5. 2) Serotype 3a is a recommended second component for a 
multivalent vaccine. Given the prevalence of serogroup 3 infection, our modeling 
indicates that serotype 3a could offer protection against the immunologically 
important 3b and may further enhance coverage through shared helical conformations 
that are induced by glucosylation on rhamnose A. 3) A serogroup 5 vaccine component 
is likely unnecessary given the low prevalence of infection and possible coverage from 
the serotype 2a-3Ac and 3a components. 
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The recommended vaccine components, serotypes 2a (with O-acetylation) and 3a, 
provide direct coverage against highly prevalent serotypes and exhibit the range of 
epitopes found on the remaining S. flexneri serotypes (except for serotype 6). As cross-
protection against non-vaccine serotypes is supported by our conformational analysis 
of serogroups Y, 2, 3, and 5, which display shared conformations and similar 
conformational trends for given substitutions; a multivalent vaccine offering broad-
coverage against Shigella infection is found to be promising. 
Prominent topics arising as future work from this dissertation include: 
For Shigella, the investigation of the conformations of S. flexneri O-Ags can be further 
extended from our study of serogroups 2, 3 and 5 (Fig. 6.1a) to the remaining 
prevalent strains – serogroup 1 and serotype 6. Serogroup 1 (Fig. 6.1b) is defined by 
glucosylation at O-4 of GlcNAc D, which could expand our set of heuristics to include 
the effects due to conformational shifts in the C-D linkage. However, the shared 
substitutions at rhamnose A and C, affords insight from our established heuristics. 
According to our first heuristic, O-acetylation on rhamnose C (serotype 1b) is predicted 
to restrict the chain to predominantly C-curve conformations. Substitution on O-3 of 
rhamnose A (O-acetylation in 1a and 1b as well as glucosylation for 1d) are predicted 
to have helical conformations as in serotypes 2a-3Ac, 2b, 3a and 5b. Serotype 6 (Fig. 
6.1c) is also projected to have a helical conformation with O-3-acetylation on 
rhamnose A but to ascertain the effect of the alterations in backbone structure 
(residues C and D) will require further inquiry. 
Modeling of the conformations of these serotypes can further refine our set of 
heuristics as well as analyze the expected cross-protection from a Shigella vaccine  
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Figure 6.1: Line structures of serogroups 2, 3 and 5 (a) studied in this work as well as 
the prevalent serogroup 1 (b) and serotype 6 (c) strains suggested for future study. 
 
consisting of an O-3-acetylated serotype 2a and serotype 3a (with serotype 6 and S. 
sonnei) against the remaining non-vaccine O-Ags. 
For N. meningitidis serogroup A (Fig. 6.2a), while the second publication found the 
carba-MenA analogue (Fig. 6.2b) to be unlikely to elicit strong cross-protection against 
serogroup A infection, further study is needed to investigate the detected bactericidal 
response for a Carba-MenA chain of moderate length and determine whether length 
or conformation is the critical factor determining immunogenicity. As a chemically-
stabilized MenA vaccine antigen is still required, MD simulations could also investigate 
whether a phosphono-meningococcal serogroup (Fig. 6.2c), with methylene 
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substitution in the phosphodiester linkage, could exhibit greater conformational 
similarity with the native serogroup A RU than the Carba-MenA mimic. 
 
Figure 6.2: Monosaccharide RUs of the (a) native serogroup A, (b) carba-MenA and (c) 
phosphono-MenA. The substitution of an oxygen atom for a methylene group is 
marked in red for the Carba-MenA and Phosphono-MenA RUs. 
 
In addition to these studies, further experimental evidence can be sought to 
corroborate the theoretical aspects of molecular modeling. As computational power 
increases, MD simulations can investigate larger systems in ever-greater detail and can 
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